The University of San Francisco

USF Scholarship: a digital repository @ Gleeson Library | Geschke
Center
Master's Theses

Theses, Dissertations, Capstones and Projects

Summer 8-27-2020

An Investigation of Antenna, Ligand Side-chain, and Metal Ion
Effects on the Optical and MRI Properties of Bimodal Lanthanide
(III) Complexes
Marisa Poveda
mpoveda@dons.usfca.edu

Follow this and additional works at: https://repository.usfca.edu/thes
Part of the Inorganic Chemistry Commons

Recommended Citation
Poveda, Marisa, "An Investigation of Antenna, Ligand Side-chain, and Metal Ion Effects on the Optical and
MRI Properties of Bimodal Lanthanide (III) Complexes" (2020). Master's Theses. 1329.
https://repository.usfca.edu/thes/1329

This Thesis is brought to you for free and open access by the Theses, Dissertations, Capstones and Projects at USF
Scholarship: a digital repository @ Gleeson Library | Geschke Center. It has been accepted for inclusion in Master's
Theses by an authorized administrator of USF Scholarship: a digital repository @ Gleeson Library | Geschke Center.
For more information, please contact repository@usfca.edu.

An Investigation of Antenna, Ligand Side-chain, and Metal Ion Effects on the
Optical and MRI Properties of Bimodal Lanthanide (III) Complexes

A thesis Presented to the faculty
of the Department of Chemistry
at the University of San Francisco
in partial fulfillment of the requirements
for the Degree of Master of Science in Chemistry

Written by

Marisa Poveda
Bachelor of Science in Chemistry
University of New Mexico, Albuquerque, NM
August 27, 2020

An Investigation of Antenna, Ligand Side-chain, and Metal Ion Effects on the Optical and
MRI Properties of Bimodal Lanthanide (III) Complexes
Thesis written by Marisa Poveda
This thesis is written under the guidance of the Faculty Advisory Committee, and approved by all its
members, has been accepted in partial fulfillment
of the requirements for the degree of

Master of Science
in Chemistry
at
the University of San Francisco

Thesis Committee

Osasere Evbuomwan, Ph.D.
Research Advisor

Date

Lawrence Margerum, Ph.D.
Professor

Date

Ryan West, Ph.D.
Assistant Professor

Date

Marcelo Camperi, Ph.D.
Dean, College of Arts and Sciences

Date

Acknowledgement
First, I would like to thank my research advisor, Dr. Evbuomwan, for her mentorship
during my time at USF. I have learned so much from her that I will use throughout my career and
life and am honored to have worked with her these last two years. Her guidance has allowed me
to begin my career as a research chemist, and I will forever be grateful to her. I would also like to
thank Dr. Margerum and Dr. West for being part of my thesis committee and taking the time to
give great constructive feedback. Thank you to the USF staff including Jeff Oda, Matt Helm,
Deidre Shymanski, John Hendrix, and Angela Qin for their help and support throughout my time
as a graduate student. Thank you to all of the professors at USF for your guidance. I would also
like to thank Dr. Tzagarakis-Foster and Dr. Kim for teaching me about cell culture. It was such a
great experience to work collaboratively with the Biology Department. And thank you to Dr.
Terefe Habteyes from the University of New Mexico who provided me my first introduction to
Chemistry research, and to Ms. Ballard who set me on my way to becoming a chemist.

I would like to acknowledge Dr. Kylie Allen from Virginia Tech and Dr. James Ratnakar
at the Advanced Imaging Research Center at UT Southwestern for their help in acquisition of data
for my projects as well as Dr. Whitehead for his generous funding of this research over the summer.

Thank you to the graduate students at USF for all of the support and fun times. I could not
have asked for a better group of people to experience graduate school with even if our time together
was cut short. And thank you to the best group in the world: Matt, Brooke, Holly, and Megan. It
has been such a pleasure to work with such incredible people. I wish you all the greatest successes
in your future endeavors.

And last but not least I would like to thank my parents for their constant support throughout
this experience. I would not be where I am today without you and your encouragement. Thank you
for all you’ve done and continue to do for me. And to my grandma who I wish was here to see me
graduate, thank you for always believing in me.

Table of Contents
Abstract ........................................................................................................................................... v
Chapter 1. An Introduction to Magnetic Resonance Imaging (MRI) and Optical Imaging ...... 1
1.1 Lanthanide Ions ................................................................................................................................. 1
1.2 Magnetic Resonance Imaging........................................................................................................... 2
1.3 MRI Contrast Agents ........................................................................................................................ 6
1.4 Chemical Exchange Saturation Transfer (CEST) ........................................................................ 11
1.5 Lanthanide Complexes as PARACEST Agents............................................................................ 14
1.6 Responsive PARACEST Agents..................................................................................................... 15
1.7 Photophysical Properties of Lanthanide (III) ions ....................................................................... 22
1.8 Lanthanide-based Bimodal Imaging Agents................................................................................. 23
1.9 Research Goals ................................................................................................................................ 26
1.10 References ...................................................................................................................................... 27

Chapter 2. Impact of Quinoline-amide Substituent Position on the Optical Properties of
Europium(III) Complexes ........................................................................................................... 34
Abstract .................................................................................................................................................. 34
2.1 Introduction ..................................................................................................................................... 35
2.2 Experimental Methods .................................................................................................................... 40
2.3 Results and Discussion .................................................................................................................... 53
2.4 Conclusion ........................................................................................................................................ 65
2.5 References ........................................................................................................................................ 67

Chapter 3. Effects of Antenna and Side-Chain Identities on the Optical and PARACEST MRI
Properties of Tb(III) and Eu(III) Complexes ............................................................................. 71
Abstract .................................................................................................................................................. 71
3.1 Introduction ..................................................................................................................................... 72
3.2 Experimental Methods .................................................................................................................... 79
3.3 Results and Discussion .................................................................................................................... 95
3.4 Conclusion ...................................................................................................................................... 105
3.5 Future Work .................................................................................................................................. 106
3.6 References ...................................................................................................................................... 107

Appendix A. Supporting Data .................................................................................................... 112
A.1 NMR Spectra ................................................................................................................................ 112
A.2 HPLC Methods and Chromatograms ........................................................................................ 145
A.3 Phosphorescence Spectra ............................................................................................................. 165

iv

Abstract
Magnetic Resonance Imaging (MRI) is a leading anatomical imaging modality for disease
diagnosis. With the aid of Gd3+ based contrast agents, high resolution images of biological structures can
be obtained. However, there is an increased need for contrast agents that are responsive to specific analytes
and chemical environments. Paramagnetic Chemical Exchange Saturation Transfer (PARACEST) agents
that utilize a paramagnetic lanthanide ion chelated with a ligand have shown great promise in this area.
Lanthanide ions also possess luminescence properties that do not suffer from common limitations of
conventional optical imaging agents such as autofluorescence and photobleaching. The projects described
in this thesis aim to capitalize on the dual MRI and optical characteristics of lanthanide ions through the
synthesis and characterization of a series of bimodal Eu3+ and Tb3+ complexes. Chapter one contains an
overview of lanthanide complexes, MRI, and optical imaging. Chapter two details a study on the effect of
quinoline-amide substituent position on the optical properties and stabilities of a library of Eu3+ complexes.
In chapter three the effect of varying side-chain identities of Tb3+ and Eu3+ complexes is investigated. The
results obtained from these projects indicate that minor changes in ligand structure can have a significant
impact on the imaging properties and stabilities of these lanthanide complexes. This insight can be applied
towards further optimization of the MRI and optical properties of bimodal Ln(III) complexes.
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Chapter 1. An Introduction to Magnetic Resonance Imaging (MRI) and
Optical Imaging
1.1 Lanthanide Ions
The lanthanides appear in the Periodic Table as the inner transition metals in Period 6 (#57-70).1 They
are often visually separated from the main body of the periodic table and included with the actinides (Figure
1-1).1,2 Commonly referred to as the “rare earth elements”, the lanthanides are distinguished from other
elements by their valence f-orbitals.3 The electrons in the 4f orbitals along with those in the 5d orbitals of
lanthanides are located closer to the nucleus and are well shielded by the 5s and 5p orbitals.3 Therefore, 4f
electrons do not participate directly in bonding and, thus, their spectroscopic and magnetic properties are
not influenced by ligands.3

Figure 1-1. Lanthanide series on the Periodic Table. The Lanthanides are located in Period 6 (red box).1

Lanthanides primarily adopt the +3 oxidation state in compounds and demonstrate unique properties
that make them useful for a range of different applications; from metal making to development of
luminescent materials.1,3 Mixtures of early lanthanides have been referred to as “mischmetals” and have
been used in steelmaking to remove impurities and improve the strength of steel.2 High magnetic materials
such as alloys of samarium and cobalt have been used in headphones, microphones, magnetic switches, and
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devices in electric cars and wind turbines.2 Other lanthanides have been shown to have luminescent
properties. For example, europium oxide has been used as a red phosphor in displays and lighting, while
Nd3+, Sm3+, and Ho3+ are used in solid state lasers (Figure 1-2).2,4,5

Figure 1-2. Applications of lanthanides. The luminescent capabilities of some lanthanides have proven
useful for modern technology such as electronic displays and biomedical imaging.6
The paramagnetic and optical properties of different lanthanides have also proven interesting for
biomedical imaging applications. This has led to the development of imaging agents for disease detection,
diagnosis, and treatment.7–9 These paramagnetic and luminescent properties form the basis of this thesis
project on bimodal imaging agents with MRI and optical imaging capabilities.

1.2 Magnetic Resonance Imaging
Magnetic Resonance Imaging (MRI) is a noninvasive anatomical imaging technique that utilizes the
same basic principles as Nuclear Magnetic Resonance (NMR). The properties of NMR were first described
experimentally in 1946 by Bloch and Purcell and translated clinically by Nottingham and Aberdeen in
1980.10,11 The difference between these imaging modalities is that in NMR, the measurement of chemical
shifts produces a spectrum while MRI measures the spatial distribution of the intensity of water proton
signals in the body and yields an image.12 An example NMR spectrum and MR image are shown in Figure
1-3.
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d

Figure 1-3. Schematic of (a) an NMR spectrometer, (b) an MRI scanner, (c) an NMR spectrum of a
europium complex, and (d) an MR image of a brain.13–15

MRI utilizes certain nuclei that possess a spin property with an induced magnetic moment that
generates a local magnetic field. The 1H nucleus is the most widely studied due to the prevalence of water
molecules in the body.16 The process by which these nuclei produce an image can be seen in Figure 1-4.
When a strong, external magnetic field (B0) is applied, the nuclei are aligned either parallel or perpendicular
to the external field. The nuclei then precess around the B0 axis in a similar manner as a gyroscope under
the influence of Earth’s magnetic field. The velocity of their rotation is referred to as the Larmor frequency.
In order to acquire an image, a radiofrequency pulse (B1) is applied perpendicularly to B0. The nuclei
absorb energy from the pulse, causing a change in the net magnetization of the spins.17,18 The energy emitted
by the nuclei during this transition induces a voltage that is detected by a wire coil and displayed as a freeinduction decay (FID). Lastly, the FID is resolved through Fourier transformation into an image (MRI) or
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a spectrum (NMR).17,18 The varying shades of black and white that outline different structures in an MR
image is due to the proportions of water found in different parts of the body.19

Figure 1-4. (a) Random orientation of hydrogen nuclei in the absence of a magnetic field. (b) Hydrogen
nuclei aligned parallel to the applied magnetic field B0 with a net magnetic moment Mz. (c) After
application of the RF pulse perpendicularly to B0, the net magnetic moment tilts. (d) The nuclei realign
after the RF pulse stops and release energy to produce the MR signal.18
A high resolution MR image can be generated because 1H nuclei in different tissue environments
have different relaxation times.16 Relaxation refers to the time it takes for the nuclei’s spin to return to
equilibrium after an RF pulse is applied. These times depend on the molecular characteristics of the tissue.20
There are two types of relaxation processes, T1 and T2. These relaxation processes are illustrated in Figure
1-5. T1 relaxation, also known as longitudinal or spin-lattice relaxation, is a measure of the time it takes for
the energy introduced by the RF pulse to be transferred back to the surroundings. This causes a recovery of
the magnetization along the z-axis. T2 relaxation known as transverse or spin-spin relaxation refers to the
loss of phase coherence in the transverse plane. The spinning nuclei move to random orientations in the
transverse plane after the RF pulse ends, which decreases the transverse magnetization.
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Figure 1-5. Left: Diagram of T1 relaxation. After the RF pulse, the spin is inverted 180. Upon relaxation,
the spin orientation returns to its position aligned with the Mz axis. Right: Diagram of T2 relaxation. After
a 90 RF pulse, the spin is oriented in the xy-plane. As it relaxes, the spins “fan out,” reduces the net
magnetization in the xy-plane.19
Due to different tissues having unique relaxation times, changes in these times can indicate
abnormalities in the body. For example, an increase in fat seen in muscle atrophy shortens longitudinal and
transverse relaxation times while elevated water in muscle edema will lengthen both relaxation times. 21
Multiple pulse sequences are used to detect differences in relaxation times, and the image produced is a
result of different densities of signals from the water protons.16

MRI has been a leading imaging modality in the diagnosis and study of various diseases including
prostate cancer, uterine cancer, certain liver cancers, and metastases to the bone and brain that cannot be
imaged well with other modalities such as computed tomography (CT) (Figure 1-6).22–25 Another benefit of
MRI is the use of non-ionizing radiation to generate the image, which is less detrimental to patients who
may require several scans over their lifetime.18
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Figure 1-6. MR images (A, B) and CT images (C, D) of the same brain. Yellow arrows in Figure 6A and
6B point to small lesions that cannot be seen in Figures 6C and 6D.26

1.3 MRI Contrast Agents
Although MRI has been shown to produce high quality anatomical images, it can be difficult to
distinguish finer details in structures such as brain tumors.27 To overcome this limitation, MRI contrast
agents are often used to increase the contrast between normal and abnormal tissue. It is estimated that 25%
of all clinical MRI examinations utilize contrast agents especially for imaging the brain and spine.28 There
are many types of contrast agents and these can be categorized by a variety of factors including magnetic
properties, chemical composition, method of administration, effect on the MR image, biodistribution, and
application.29 Most contrast agents can be classified as T1 or T2 agents as they produce contrast by
shortening the longitudinal or transverse relaxation times of tissue.30 These agents will be further explored
in the following sections.
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T1 Agents
T1 shortening agents are compounds that shorten the longitudinal relaxation time of tissue. This causes
an increase in signal intensity of T1-weighted MR images resulting in a brightening of the image to produce
contrast.31 Typical T1 shortening agents are compounds that utilize paramagnetic ions such as Gd 3+ and
Mn2+, which have 7 and 5 unpaired electrons, respectively.32 Research studies show that the unpaired
electrons of paramagnetic ions decrease the proton relaxation times.27

To date, the most commonly used contrast agents for clinical applications are gadolinium-based
contrast agents (GBCAs).18 There are currently eight FDA-approved GBCAs in use clinically (Figure 17).33 Gd3+ is the preferred paramagnetic ion for T1-weighted MRI applications because of its high magnetic
moment and number of unpaired electrons.34 GBCAs can act as both T1 and T2 agents depending on
concentration.34 At low concentrations, GBCAs act as T1 shortening agents while T2 shortening occurs at
higher concentrations.34 GBCAs are therefore preferred as T1 agents because the use of higher
concentrations of GBCAs can potentially be harmful due to the toxicity of free Gd3+ ions.34 When chelated
to appropriate organic ligands, the agents pass through the kidneys quickly without the metal ion
dissociating.34,35 Limiting doses of GBCAs to 0.1 - 0.3 mmol/kg of body weight is of particular importance
for patients with decreased renal function as higher concentrations increase the possibility of heavy metal
poisoning over time.35

Figure 1-7. FDA approved gadolinium-based contrast agents33
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Due to heavy clinical use of GBCAs, their properties are well-studied. Low molecular weight Gd3+
complexes can effectively detect and diagnose disrupted blood-brain barriers in central nervous system
(CNS) diseases such as multiple sclerosis and brain tumors.36 Furthermore, in the diagnosis of soft tissue
injury, GBCAs can make a proper diagnosis three times as likely than use of MRI without contrast.37
Overall, GBCAs are especially useful in the identification and enhancement of soft tissue injuries and brain
lesions.37 A comparison of MR images acquired with and without gadolinium contrast can be found in
Figure 1-8.

Figure 1-8. T1-weighted images of a patient presenting with paresthesia or numbness in the body. The
pre-contrast image (left) shows an abnormality, though faint and hard to identify. The post-contrast image
(right) shows bright enhancement of the lesion and was used to help characterize the abnormality.38

Manganese-based chelates represent another group of paramagnetic compounds studied for their
MRI applications. Mn2+ ions have been found to accumulate within cells via L-type calcium channels and
increase intracellular longitudinal relaxation time.39 Similar to gadolinium agents, high concentrations of
free Mn2+ ions pose cardiotoxicity and neurotoxicity risks.40,41 Manganese-based contrast agents are
therefore designed to be chelated with a ligand that limits the concentration of free Mn 2+ in the body.
Mangafodipir trisodium (Mn-DPDP), an FDA-approved Mn2+ contrast agent for liver and pancreas
imaging, is one such compound.42 Upon injection, the metal complex is taken up by the liver, and allows
MR images to be acquired.43
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MR imaging using manganese-based contrast agents is referred to as manganese-enhanced MRI
(MEMRI) and has also been explored in animal studies as a potential approach to functional brain
imaging.44,45 A comparison of images of a liver lesion acquired through CT and MEMRI can be found in
Figure 1-9. The MEMRI image of the liver shows clearer defined margins of the hepatic lesion compared
to images acquired by CT.

Figure 1-9. CT (left, middle) and MR (right) images of a liver of a 51-year-old male upon injection of the
FDA-approved Mangafodipir trisodium contrast agent. An enhanced view of a lesion (white arrow) can
be seen upon MR imaging.46

T2 Agents
T2 agents represent another class of MRI contrast agents that generate contrast through decreasing
the transverse relaxation time of water molecules. This shortening of the transverse relaxation causes a
darkening of the MR image through decreasing signal intensity.31 Though not as commonly used as T1
weighted MRI, there have been applications of Gd3+ and Dy3+ nanoparticles for acquisition of T2 weighted
MR images. A comparison of T1- and T2-weighted images are shown in Figure 1-10. Areas that appear
bright in the T1-weighted image appear darker in the T2-weighted image.
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Figure 1-10. MR images acquired through T1 and T2 imaging of a patient’s brain.47
One of the most commonly studied groups of T2-shortening contrast agents are superparamagnetic
iron oxide (SPIO) nanoparticles. These nanoparticles have the general formula Fe 23+O3M2+O where M is a
divalent metal such as iron, manganese, nickel, cobalt, or magnesium.48 SPIO nanoparticles are useful for
bowel contrast, liver and spleen imaging, and MR angiography. 49–51 Negative contrast is beneficial when
imaging the bowel as it decreases noise and other artifacts.52 Iron oxide nanoparticles can also reduce T2
signal in healthy lymph nodes and liver tissue while abnormalities are unaffected, thus allowing for better
discernment of diseased tissue.53–55

As previously mentioned, Gd3+-based contrast agents can act as T1 and T2 shortening agents though
they are typically preferred for their T1-shortening characteristics as this requires lower concentrations.
Takaya and coworkers suggested that utilizing transverse relaxation in MR cholangiopancreatography to
visualize biliary structures in diagnosis of neonatal cholestasis could be an application of GBCAs for T 2weighted imaging. Bile and water have been shown to have long transverse relaxation times, allowing for
easier visualization of bile over background signal.56,57 Some researchers have explored combining the
preferred T1-shortening characteristics of Gd3+ with the significant T2-shortening effects of other lanthanide
ions such as Dy3+, to design agents that have dual T1/T2 properties.58

PARACEST Agents
Conventional T1- and T2-shortening agents, while having great benefits in the realm of MRI, have
some limitations with respect to disease diagnosis and specificity. Typical applications of MR contrast
agents rely upon the increased uptake of an agent by permeable tumors and less on specific targeting of
molecules of interest.59 There is a need for the creation of contrast agents that will bind to particular
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antibodies, metals, or other targets associated with different diseases. While some Gd-based MR contrast
agents are capable of detecting cancer-related targets such as the HER-2/neu receptor, there is still a need
for ‘smart’ agents that are responsive to their chemical environment. 60 Paramagnetic chemical exchange
saturation transfer (PARACEST) agents are a class of MRI contrast agents that have shown great promise
in this area.

1.4 Chemical Exchange Saturation Transfer (CEST)
Chemical Exchange Saturation Transfer (CEST) refers to the generation of contrast through
chemical exchange of two pools of protons; bulk water surrounding the imaging agent and labile protons
associated with the agent. For PARACEST agents, the exchangeable protons are typically located on a
water molecule coordinated to a paramagnetic lanthanide ion chelated by a multidentate ligand. Labile
protons can also be found on amide and hydroxyl functional groups on the chelating ligand. Examples of
different pools of protons can be seen in Figure 1-11.

Figure 1-11. PARACEST agent with different pools of exchangeable protons: bulk water (blue), bound
water (red), and amide protons (green).
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Figure 1-12. Difference in NMR signal between CEST signal and relaxation of protons back to
equilibrium. For CEST, chemical exchange occurs to decrease both bulk water and bound proton signals
while for the relaxation pathway, NMR signal remains unchanged.61
The CEST mechanism can be understood as two independent equilibria processes that happen
between the two pools of exchangeable protons (Figure 1-12). A pre-saturation pulse is applied to decrease
the bulk magnetization of the bound water protons by increasing the number of spins aligned against the
magnetic field (increased spin population in the higher energy state). Due to chemical exchange, low energy
and high energy spins exchange between the two proton pools. This results in a saturation of the bulk water
signal due to a net reduction of the bulk magnetization vector along the z-axis. Upon application of a 90o
radiofrequency (RF) pulse, the bulk water proton signal intensity is decreased due to chemical exchange
which results in a darkening effect in an MR image (Figure 13e).61,62
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Figure 1-13. T1 weighted (T1w) and CEST images of the thigh of a healthy mouse after injection of a
Eu2+- based contrast agent. Upon oxidation to Eu3+, the compound is converted from a T1 agent to a
PARACEST agent. T1 weighted images were acquired at a) pre‐injection, b) 5 min, c) 12 min, d) 16 min
and e) the CEST image at 17 min.63

Multiple conditions must be met for CEST to occur instead of T1 relaxation. The exchange process
must occur between two magnetically distinct environments and must be slow on the NMR scale. This
means that the rate of exchange (kex) must be less than the frequency difference between the two chemical
environments ().64 For this reason, agents with slow-to-intermediate water proton exchange are usually
preferred for PARACEST applications. The relaxation times of the two pools of protons must also be long
relative to the exchange rates. Long relaxation times prevent the protons from relaxing back to equilibrium
before chemical exchange can occur. The difference between an NMR spectrum acquired through CEST
versus that of protons that relax back to equilibrium is shown in the top row of Figure 1-12. If the relaxation
times of the proton pools are short compared to the exchange rates, the protons will relax back to
equilibrium without exchanging and a signal reduction due to CEST will not be observed. However, if
relaxation times are long, a decrease of both Pool B (bulk water protons) and Pool A (labile protons) signals
will occur.61,65

CEST spectra
In the study of PARACEST agents, characterization of the chemical exchange in a system is
achieved through acquisition of a Z-spectrum (or CEST spectrum) which is a plot of bulk water signal
(Ms/M0) versus saturation frequency that is acquired through selective pre-saturation over a range of
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frequencies.66 A sample Z-spectrum of a Eu3+-DOTA complex can be found in Figure 1-14. The large peak
at 0 ppm corresponds to the direct saturation of bulk water. The other peak at +50 ppm represents signal
produced from the chemical exchange of bound water molecules of the complex with bulk water molecules.
Using this CEST signal, one can determine the percent decrease in intensity of the bulk water signal as a
function of irradiation frequency.67

Figure 1-14. Sample CEST spectrum of a Eu3+ complex and its corresponding NMR spectrum. The
spectrum shows the bound water resonance residing 50 ppm away from the bulk water resonance. 68

1.5 Lanthanide Complexes as PARACEST Agents
Early studies of lanthanide complexes for MR imaging showed that chemical exchange between OH and -NH groups on Diamagnetic Chemical Exchange Saturation (DIACEST) agents and bulk solvent
could produce an MR signal.64 However, due to the exchangeable protons residing only 1-5 ppm away from
the bulk water signal, it was very difficult to selectively saturate these labile protons without directly
affecting the bulk water signal.64,69 For detection of an optimal CEST signal, chemical shift () must be
larger than the exchange rate between bound and bulk water protons (kex).67 One study showed that
paramagnetic Eu3+ DOTA-tetraamide complexes having slow-to-intermediate water exchange kinetics
possessed highly shifted CEST exchange peaks ten to hundreds of ppm away from the bulk water signal.62,68
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These larger chemical shifts associated with PARACEST agents allows for acquisition of CEST signal in
agents with faster water exchange kinetics and ensures that selective saturation of bound water protons does
not result in direct saturation of bulk water protons.69,70 Though it is feasible with the larger  of
PARACEST agents to use fast exchanging systems, production of CEST signal in this case require more
RF power for saturation, which results in significant tissue heating.71 To avoid this issue, PARACEST
agents with slow-to-intermediate exchange rates are generally preferred.71

The vast majority of PARACEST agents reported to date produce contrast through the slow-tointermediate exchange of bound and bulk water molecules.68 Most of these complexes comprise a
paramagnetic lanthanide ion chelated with a derivative of the DOTA-tetraamide ligand (Figure 1-11).68 The
CEST signal arising from bound water exchange in a Eu-DOTA-tetraamide complex is usually detected
near +50 ppm from bulk water, while that of a Nd-DOTA-tetraamide complex is typically found around 32 ppm.72,73 For Dy3+ complexes, the chemical shift difference between the bound and bulk water protons
is as large as -720 ppm.72

The presence of amide protons on the DOTA-tetraamide ligand provides another pool of protons
that can exchange with bulk water protons. For example, Yb-DOTA-tetraamide complexes possess a higher
number of amide protons compared to bound water protons, which results in a larger PARACEST signal
due to the presence of more exchangeable protons.74,75 However, the amide proton CEST signal in these
complexes is shifted only about 20 ppm from the bulk water signal.76 Dy-DOTAM complexes also generate
CEST signal from the highly shifted amide proton resonance residing +80 ppm away from the bulk water
resonance.68

Incorporation of hydroxyl and hydroxyethyl side-chains into the DOTA structure is another
approach in the design of PARACEST agents. Although this method increases the number of exchangeable
protons available for CEST, the weak ligand field due to the hydroxyl groups leads to small  and lowers
the magnitude of the CEST signal.61

1.6 Responsive PARACEST Agents
The design of PARACEST agents that are responsive to a variety of analytes and chemical
environments has been of particular interest in the biomedical imaging field. The response of these agents
is typically measured through alterations of exchange rates, ligand structure, and chemical shifts, in the
presence of the analyte of interest.68,77–79 Phenyl boronate groups incorporated into the ligand structure of a
Eu3+ complex allows the agent act as a glucose sensor (Figure 1-15).78 The two appended phenylboronic
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acid groups on the Eu3+ complex form a bridge to capture glucose by forming a cyclic ester bond with the
cis-diol group in glucose. The captured glucose molecule slows the rate of bound and bulk water exchange
and can be imaged via MRI. As the concentration of glucose in solution increased, the CEST signal also
increased.

Figure 1-15. Left: ligand with two phenyl boronate substituents. Right: CEST images of phantoms with
10 mM Eu3+ complex and increasing concentrations of glucose from 5 mM to 20 mM. As concentration
of glucose increases, CEST signal also increases.78

Likewise, the addition of a p-NO2-phenyl substituent to a Eu3+-DOTA-tetraamide complex
furnished this PARACEST agent with redox sensitivity.77 Upon reduction to p-NH2-phenyl, the CEST
image darkened (Figure 1-16). The electron-donating p-NH2-phenyl substituent pushes electron density
from the coordinated amide to the Eu3+ ion, weakening the metal-water interaction and increasing the water
exchange rate. By monitoring the CEST signal, one can track the reduction of NO2 to NH2, thus
demonstrating the potential of using this complex to identify highly reducing environments in vitro.

Figure 1-16. Difference in CEST images of an oxidized and reduced Eu3+ complex with p-NO2 and pNH2 side-chains.77

Another strategy employed in the design of responsive agents is to incorporate a substituent that
causes a change in the chemical shift of bound water upon interacting with the analyte of interest or when
in certain physiological environments. Replacement of one amide side-chain in a Eu3+-DOTA-Gly complex
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with a ketone-phenol group induced pH sensitivity in this complex (Figure 1-17). As the pH of the solution
increased from pH 6.0 to 7.6, deprotonation of the phenolic proton occurred and resulted in a gradual change
in chemical shift of the water exchange peak from +50 to +54 ppm.79

Figure 1-17. Left: Eu-DOTA-Gly complex with a ketone-phenol group. Right: CEST spectra of the EuDOTA-Gly complex recorded at 9.4 T and 298 K. The insert depicts an expanded view of the water
exchange peak as a function of pH.79

PARACEST agents have the potential to detect metabolites through binding of the analyte of
interest to the inner coordination sphere of the lanthanide ion. A Yb3+ complex with a heptadentate ligand
and six exchangeable amide protons (MBDO3AM) was developed to detect the presence of lactate which
is associated with the formation of metastases.

80,81

The lactate molecule binds to the inner coordination

sphere of the Ln3+ ion and causes a change in the amide chemical shift from -28.5 ppm to -20 ppm that is
proportional to the concentration of the species of interest.80 This change in the chemical shift allows for
the quantitative measurement of lactate.80 The ligand used in this study and the CEST signal following
binding of lactate are shown in Figure 1-18.
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Figure 1-18. Left: The MBDO3AM ligand. Right: CEST spectra of a 30 mM solution of Yb3+MBDO3AM complex free (□) and fully bound to l-lactate (▪). Upon binding to lactate the amide chemical
shift of the Yb3+-MBDO3AM complex changes from -28.5 ppm to -20 ppm.80

PARACEST agents have the potential to detect several metal ions in solution by several
mechanisms.

For

example,

a

[Eu(dotampy)]

complex

containing

N,N-bis(2-pyridyl-

methyl)ethylenediamine groups was capable of detecting zinc ions (Figure 1-19) via equilibrium binding
to the pyridyl groups on this complex.82 The CEST signal around 50 ppm decreased and this signal change
was attributed to the presence of a coordinated hydroxyl group at this pH on the bound Zn2+ ion that
accelerated water proton exchange, and led to broadening of the water exchange signal at 50 ppm.

Similarly, Angelovski and coworkers designed a Yb3+-based PARACEST agent with four
iminodiacetate side-chains capable of binding metal ions like Ca2+.83 This study showed a similar
phenomenon whereby the CEST effect was altered upon binding to Ca2+ due to a deceleration of the amide
exchange rate. The ligand used in this study and CEST images upon binding to Ca 2+ can be found in Figure
1-20.
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Figure 1-19. Left: Eu(dotampy) complex binding to Zn2+. A coordinated water molecule on Zn2+ is
deprotonated at physiological pH to a hydroxyl group. Right: Upon Zn2+ binding to the Eu(dotampy)
complex, the CEST signal at 50 ppm broadens at pH 7 and practically disappears at pH 8.82

Figure 1-20. Left: Yb3+ and Eu3+ complex designed to bind to Ca2+. Right: CEST spectra of a twenty
millimolar aqueous solution of YbL1 in the absence (▴) and in the presence of 5 (■) and 100 equiv (♦) of
Ca2+. Upon binding to Ca2+, the CEST signal of the Yb3+ complex decreases .83
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Changes in redox properties of tissue can be indicative of diseases like cancer or conditions such
as hypoxia. The need to detect these types of conditions has inspired the design of redox-responsive
PARACEST agents. These agents typically produce altered PARACEST signals due to redox-induced
changes in the oxidation state of either the metal center or the ligand. One such compound that has been
studied is a Eu2+ complex with glycinate side-chains (Figure 1-21).63 The Eu2+ complex acts as a T1 agent
because it is isoelectronic with Gd3+. Upon oxidation to Eu3+, the complex produces a CEST effect that
detects oxidative environments. The complex could not be used to quantify the amount of oxidant present,
but instead was used to detect oxidation without knowledge of the concentration of the probe.

Figure 1-21. T1 weighted and CEST image of the thigh muscle of a healthy mouse post-injection of a
Eu2+-Gly complex. After 17 min, the complex was oxidized from Eu2+ to Eu3+ and a CEST image was
acquired.63
A significant advantage of responsive PARACEST agents is the concentration-independent
approach to signal acquisition which negates the need to know the exact concentration of contrast agent in
a region of interest.84 The use of concentration-independent methods for monitoring responsiveness can be
accomplished by the injection of two agents, one responsive and one unresponsive. Aime et al. have used
this approach to monitor pH changes with the aid of two lanthanide complexes of the same ligand, YbDOTAM-Gly and Eu-DOTAM-Gly.85 The Yb(III) agent, with amide protons shifted 16 ppm upfield,
responded differently to pH compared to the Eu(III) complex which produced a CEST effect through the
bound water protons shifted 40 ppm downfield from the chemical shift of the bulk water.85 They found that
the ratios of the CEST signals from these two complexes could be used to determine pH without knowing
the concentration of either agent.85 The ratio of the CEST signals from pH 6.5 to 8.5 is shown in Figure 122.
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Figure 1-22. Left: Structure of the DOTAM-Gly ligand. Eu- and Yb-DOTAM-Gly complexes were
synthesized. Right: Plot of the pH dependence resulting from the ratiometric method following irradiation
of 10 mM Eu-DOTAM-Gly and 12.5 mM Yb-DOTAM-Gly. The CEST effect was due to the pH
dependence of the amide proton exchange for the Yb3+ complex while the water proton exchange signal
from the Eu3+ showed no pH dependence.85

Another concentration-independent approach involves the injection of one agent with two chemical
exchange sites, one of which is responsive, and the other unresponsive to the analyte of interest. Sheth and
coworkers demonstrated the effectiveness of this method by using a single Yb-DO3A-oAA complex with
exchangeable amide and amine sites to monitor pH.86 The ratio of CEST signal for both exchangeable
groups correlated with pH and was used to measure pH independent of concentration (Figure 1-23).

Figure 1-23. Dependence of CEST on pH using a Yb-DO3A-oAA complex (top). (A) % CEST signal as
a function of pH of the amide site, (B) % CEST signal as a function of pH of the amine site, (C) The log 10
of the ratio of CEST signal of the amide and amine sites as a function of pH. The log10 of the ratio of
CEST signal of the amide group and amine group show a correlation with pH.86
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In vitro studies of PARACEST agents have demonstrated the promise of applying PARACEST
agents in vivo. The possibility of turning the PARACEST MR signal “on” and “off” with a selective
radiofrequency pulse eliminates the need to acquire a full pre-contrast MRI image prior to the
administration of the contrast agent.18 This could potentially shorten the MR scan and alleviate some anxiety
for the patient. Additionally, PARACEST agents have the potential to not only provide anatomical
information, but also provide physiological information in vivo. This particular feature could significantly
improve the efficacy of disease diagnosis and treatment.

1.7 Photophysical Properties of Lanthanide (III) ions
Lanthanide ions emit light after excitation that spans the UV-NIR regions of the electromagnetic
spectrum (Figure 1-24).87 This broad span of emission wavelengths allows the development of probes with
varied lanthanide metal centers and the same ligand scaffold to fit various applications.

Figure 1-24. Emission spectra of different lanthanide ions.89

The excited Eu3+ and Tb3+ metal ions, which emit light in the red and green visible region
respectively, have narrow emission peaks, making their signal easier to separate from that of conventional
fluorophores.87,91,92 Most lanthanide ions also possess long-lived luminescence lifetimes of 0.1 - 1 ms, which
is ideal for time-gated applications.93,94 This enables selective acquisition of luminescence signal after
background autofluorescence has dissipated.94 A general depiction of selective signal acquisition through
time-gated measurements is shown in Figure 1-25.
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Figure 1-25. General diagram of time resolved luminescence measurements. Lanthanides have long-lived
luminescence lifetimes that allow for signal measurement when background autofluorescence has
dissipated.94

1.8 Lanthanide-based Bimodal Imaging Agents
Given that lanthanide complexes exhibit both MRI and optical imaging capabilities, there exists an
opportunity to develop lanthanide-based bimodal imaging agents that incorporate both of these imaging
capabilities. A typical disadvantage to MRI is its low sensitivity, while optical imaging is known to be
highly sensitive.18 The combination of these two imaging modalities with complementary levels of
sensitivity provides an opportunity to acquire physiological information at the macro- and molecular scale.18
For example, a lanthanide complex with both MR and optical imaging capabilities could be employed in
the context of image-guided tumor resection wherein a preoperative MRI scan is used to localize the bulk
of a tumor while intraoperative use of optical imaging would help a surgeon delineate tumor margins during
resection. Such a probe would help facilitate complete removal of cancerous tissue while minimizing
excessive removal of healthy tissue.

Several approaches to developing bimodal imaging probes with MRI and optical imaging properties
have been proposed. In one study, the organic dye indocyanine green (ICG) was administered to patients
after a gadolinium MR contrast agent.95 The results indicated that both imaging modalities were capable of
differentiating between healthy and malignant breast tissue. It was also suggested that monitoring ICG
permeability in conjunction with MR images could offer increased ability to differentiate cancerous tissue.95
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Though the two compounds used in this study have known properties and proven stability in the body, their
biodistributions may be different.35,96 This would make image co-registration difficult and complicate data
interpretation.

To combat the problem with differences in biodistribution between an MRI contrast agent and
fluorescent organic dye, complexes with Gd3+ that incorporate a fluorescent organic chromophore into the
ligand structure have been proposed.97–99 Gd-DOTA functionalized with 4,4,difluoro-4-bora-3a,4a-diaza8-indacene (BODIPY) as well as Gd3+ complexes tagged with fluorescein have shown success in imaging
cells (Figure 1-26).98,99 Although the issue with biodistribution could potentially be overcome by using
these compounds, the fluorescent organic dyes would still be limited by background autofluorescence and
photobleaching.100

Figure 1-26. Left: Gd-DOTA-BODIPY derivative. Right: Gd3+ complex tagged with fluorescein.98,99
Another potential approach to the development of bimodal imaging probes involves designing
nanosystems that incorporate both MRI and optical imaging agents. In one such example, the possibility of
using Mn3[Co(CN)6]2 nanocubes for T1- and T2-weighted MRI and two-photon fluorescence was
demonstrated.101 The nanocubes provided high fluorescence signal in the visible region and showed
potential for long-term cell imaging with reduced photodamage compared to typical UV imaging. The MRI
capabilities of the Mn2+ nanosystems were also more optimal than previously studied MnO compounds.
Larson et al. demonstrated similar capabilities with gold-coated iron oxide hybrid nanoparticles.102 The iron
oxide nanoparticles acted to enhance transverse relaxation while the gold nanoparticles acted as bright
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molecular specific contrast agents for optical imaging.102 Though these nanoparticle-based systems showed
promise as bimodal imaging agents, the potential risk of nanoparticle toxicity cannot be ignored.103

Lastly, the use of isostructural lanthanide complexes was proposed as a possible way to combine optical
and MR imaging capabilities. This approach typically involves two lanthanide ions, typically Gd3+ and
another luminescent lanthanide, chelated by the same ligand. The Gd3+ complex can be used for MR
imaging while the other lanthanide complex can be used for optical imaging. Allen and Meade designed
Gd3+- and Eu3+-DOTA complexes that were capable of permeating the cell membrane.104 These isostructural
complexes were designed with the aim of providing more information about cell environments and
facilitating transport of different species across cell membranes. Through T1 analysis, the Gd3+ complexes
were shown to permeate cells and provide images of them through MRI, while two-photon laser microscopy
was used to detect Eu3+ complex uptake into the cells. With both MR and optical imaging, the complexes
demonstrated their potential to monitor cell processes such as cell division over time.

Similarly, Crich and coworkers studied Gd3+- and Eu3+-HPDO3A complexes that could be internalized
by endothelial progenitor cells (Figure 1-27).105 Endothelial progenitor cells (EPCs) are commonly used in
the engineering of implantable devices such as valves. The two complexes were internalized in the EPCs
equally without affecting the biological activity of the cells and were visualized through both MR and
optical imaging. The ability to be internalized and imaged with both modalities shows the possibility for
these contrast agents to be used to monitor the transplanted cells in vivo, which could possibly replace
conventional radioactive labeling techniques.105 While the isostructural lanthanide complexes may have
similar biodistribution, using two complexes may create signal issues in one modality if one complex
significantly blocks the target of interest.106

c
Figure 1-27. Optical and MR images using Gd3+ and Eu3+ chelates to visualize endothelial progenitor
cells (EPCs). (a) Intracellular uptake of Eu-HPDO3A after 16 hr of incubation. (b) Cells showing
accumulation of Eu-HPDO3A around the nuclei. (c) MR images of Gd-HPDO3A labeled cells.105
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1.9 Research Goals
The overall goal of the projects to be described was to develop Ln3+ complexes with PARACEST MRI
and optical imaging properties. The complexes in these projects were designed to be single molecules with
MRI and optical properties arising from the same lanthanide ion. This approach takes advantage of the
luminescent capabilities of lanthanide ions such as Eu3+ and Tb3+ that have narrow emission lines and long
luminescent lifetimes for time-gated applications. Through the use of just one molecule for MR and optical
imaging, biodistribution issues can be overcome which would render image co-registration and
interpretation easier. We sought to determine how various structural factors influence the MRI and optical
properties of Ln3+ complexes with the ultimate goal of optimizing their bimodal imaging capabilities.
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Chapter 2. Impact of Quinoline-amide Substituent Position on the Optical
Properties of Europium(III) Complexes
Abstract
Lanthanide ions such as Eu(III) are known to exhibit long luminescence lifetimes, allowing for
time-resolved luminescence acquisition; however, the use of high energy lasers to directly excite these ions
could potentially be damaging to biological tissue. To address this issue, organic chromophores can be used
to absorb the incident light and transfer it to a nearby lanthanide ion. This intramolecular energy transfer
results in the indirect sensitization of the lanthanide ion luminescence. The goal of this project was to
investigate the effect of positional differences of quinoline amide substituents on the optical and MRI
properties of a library of Eu(III) complexes. Each complex comprised a Eu(III) ion chelated by an
octadentate ligand with an appended quinoline antenna. Indirect sensitization of the Eu(III) luminescence
by the quinoline pendant arm was observed for all complexes in the library, the magnitude of which was
found to be dependent on the position of the amide substituent. Quantum yield values were also found to
be affected by amide substituent position on the quinoline antenna. Triplet excited state energies of the
chromophore were determined through phosphorescence emission measurements, and the energy
difference between the triplet excited state of the ligand and emitting state of the lanthanide was used to
evaluate the efficiency of sensitization by the quinoline antenna. Using luminescence lifetime
measurements, the majority of complexes were found to possess one bound water molecule, which is
necessary for MR agents to produce a contrast signal. Kinetic stabilities of the complexes were also
investigated in order to identify the most inert complexes. Overall, direct coordination of the quinoline
antenna to the Eu(III) ion resulted in the highest emission intensities and quantum yields, but significantly
decreased kinetic stability.
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2.1 Introduction
Photophysical properties of Lanthanide ions
Lanthanide ions such as Eu3+ and Tb3+, which emit light in the red and green visible region respectively,
have photoluminescence properties that are ideal for optical imaging. These properties, which include long
luminescent lifetimes and narrow emission peaks, enable the acquisition of luminescence signal after
autofluorescence has dissipated.1 Each lanthanide ion has different emission profiles allowing for the design
of luminescent agents that span the entirety of the visible region of the electromagnetic spectrum. The
emission profiles of Tb3+ and Eu3+ can be found in Figure 2-1, spanning 475 nm – 725 nm.
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Figure 2-1. Emission spectra of a Tb3+ complex (green) and Eu3+ complex (red).

Though the emission properties of lanthanide ions show great promise to overcome the limitations
of traditional organic fluorescent dyes, free lanthanide ions do not display adequate luminescent capabilities
when excited directly due to their Laporte forbidden 4f-4f transitions.2,3 Due to this limitation, high energy
laser sources are generally required to adequately populate the excited states of the Ln(III) ions via direct
excitation, and these have the potential to damage biological tissue.3,4

The Antenna Effect
To circumvent the need for high energy excitation sources, an organic chromophore with a much
higher molar absorptivity coefficient ( = 104-105 M-1cm-1) can be used to sensitize the lanthanide ion’s
luminescence.3,5 The process of energy transfer from the antenna to the lanthanide is illustrated in Figure
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2-2. In the initial step, the chromophore is excited with a lower energy light source to promote electrons
from the singlet ground to the singlet excited state of the antenna. Through intersystem crossing, the triplet
excited state of the antenna is populated from its singlet excited state. If proper conditions between the
triplet excited state of the antenna and the emitting level of the lanthanide ion are met, some of the energy
is then transferred to the excited state of the lanthanide ion. Upon relaxation, light is emitted that is
characteristic of the lanthanide ion.5–8

Figure 2-2. A) The antenna effect. Upon excitation of the coordinated antenna, energy is transferred from
the triplet excited state of the ligand to the emitting level of the Ln(III) ion. This causes emission of light
characteristic of the lanthanide ion’s luminescence. B) 4f-4f transitions of europium and terbium
complexes and their characteristic emission wavelengths.9

There are a variety of factors that influence the efficiency of energy transfer from the antenna to
the lanthanide ion.10 One of these factors is the distance between the chromophore and the lanthanide center.
Pendant antenna have been shown to sensitize a lanthanide ion’s luminescence through the Förster
resonance energy transfer mechanism and the Dexter mechanism with efficiencies of 1/r6 and 1/er,
respectively, where r is the distance between the antenna and the lanthanide ion.10 The sensitization
efficiency of the antenna can be increased by either decreasing the linker length between the antenna and
the chelating ligand, or by using antennae that directly coordinate to the metal center.11 The ability for
directly coordinated antenna to undergo energy transfer via both the Förster and Dexter mechanisms usually
results in higher luminescence intensity.12
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Another factor that can affect the sensitization efficiency of the antenna is the energy difference
between the triplet state of the ligand and the excited states of the lanthanide ion.5 To prevent back energy
transfer from the lanthanide to the ligand, the energy difference between the triplet excited state of the
ligand and the emissive levels of the lanthanide should be at least 1850 cm -1.13 A smaller energy gap
between the triplet excited state of the ligand and the emissive levels of the lanthanide favors relaxation
through non-radiative pathways, such as back energy transfer from the lanthanide ion to the ligand, over
emission of light through the emissive levels of the lanthanide center.13 This energy gap between the triplet
excited state of the ligand and emissive levels of the lanthanide should also be less than 7000 cm-1 to allow
for energy transfer to occur.14 The electron transfer to the lanthanide ion must also be favored over
competing phosphorescence and non-radiative energy dissipation pathways.9
Lastly, the number of bound water molecules can influence the sensitization of the lanthanide ion’s
luminescence by the appended antenna. The ligand can affect the coordination environment of the
lanthanide complex, which can influence the number of water molecules that can bind to the lanthanide
ion.10 Solvent H2O molecules have the ability to quench luminescence intensity through energy loss from
highly oscillating X-H groups (X = C, N, O).15 Ligands that occupy all Ln3+ coordination sites prevent water
from coordinating to the metal ion and increase the quantum yield of the lanthanide complex by decreasing
the number of directly coordinated quenching groups.10,16

Quinolines as Efficient Antennas for Eu3+
Aromatic organic compounds such as quinolines are ideal chromophores for the sensitization of
the luminescence of several lanthanide ions.17 The excitation wavelengths of quinolines (ex > 340 nm) are
more suited for studying biological systems as lower energy light sources can be used for excitation without
harming tissue.18 Quinoline derivatives display efficient intramolecular energy transfer from the lowest
triplet state to the Eu3+ ion, and efficiently sensitize other lanthanide ions such as, Nd3+, Yb3+ and Er3+.18
This sensitization versatility, has made quinolines a very attractive class of antennae.

Figure 2-3. Left: 8-hydroxyquinoline group. Right: 3-aminoquinoline group.
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Complexes with different quinoline-based antenna have been studied. Rizzo et al. have designed
highly stable and luminescent Eu3+ complexes using a 8-hydroxyquinoline group (Figure 2-3).19,20 They
found that the 8-hydroxyquinoline antenna was an efficient sensitizer of the lanthanide ion’s luminescence
and that the complexes were stable in a variety of solvents.19,20 In another study, 3-aminoquinoline (Figure
2-3) was shown to act as an effective sensitizer of Eu3+ and Tb3+ coordinated with DTPA-bis-amide
aminoquinoline ligands.21 These complexes displayed enhanced luminescence upon binding to circulating
tumor DNA in cancer cell lines and showed potential as responsive optical imaging agents.21 In a different
study, indirectly coordinated 8-aminoquinoline derivatives were shown to greatly sensitize Eu3+ emission.22
An enhancement of the luminescence of Eu3+ by a factor of 1380 was observed relative to a Eu3+ complex
without the 8-aminoquinoline antenna, and the ligand was shown to shield the metal center from quenching
by surrounding water molecules.22 Though there has been much work with Eu3+ luminescence sensitization
by quinoline antennae, there are no reports investigating the effect of the position of the amide substituents
in these quinoline systems on the sensitization efficiency of lanthanide complexes.

Project Goal
The main objective of this project was to study the effect of varying the amide position of
aminoquinoline antenna on the photophysical properties of bimodal lanthanide complexes. To this end, a
library of Eu3+ DOTA-tetraamides with an appended aminoquinoline antenna and three acetamide sidearms was synthesized (Chart 2-1). A Eu3+ complex with a directly coordinated quinoline chromophore was
used as a control to investigate the impact of direct versus indirect coordination of the antenna. All ligands
in this study were designed to be octadentate to allow for binding of one water molecule to the metal center,
which is important for MRI agents as exchange of these bound water molecules is a potential source of
MRI contrast.23 With the presence of one water molecule, these complexes have the potential to act as both
optical imaging and MR imaging probes. The central hypothesis of this project was that changing the
position of the amide substituent on the quinoline antenna would alter the electronic properties of the
complexes and ultimately affect the photophysical properties for each complex. The ultimate goal of this
project was to identify the optimal location of the amide on the quinoline that would maximize
luminescence sensitization while preserving stability.
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Chart 2-1. Final synthesized complexes used in this study.
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2.2 Experimental Methods
Materials and Instrumentation
All reagents and solvents were purchased from commercial sources and used as received. Distilled
water was used in all reactions. Flash Chromatography was carried out using a Buchi Reveleris X2 system.
1H

and 13C NMR spectra were recorded on a Varian 500 MHz NMR spectrometer. Inductively Coupled

Plasma was performed using a Perkin Elmer 5300 DV optical emission ICP. High performance liquid
chromatography (HPLC) was performed using an Agilent 1100 Series HPLC. UV-Vis absorption spectra
were acquired using a Cary 5000 UV-Vis-NIR spectrophotometer. Luminescence studies were performed
using a Jobin-Yvon Horiba Fluoromax spectrometer.

Synthesis and Purification

Scheme 2-1. Synthesis of Eu-MP30
2‐[(1,4,7,10‐tetraazacyclododecan‐1‐yl)methyl]quinoline. (MP27): Cyclen (2.000 g, 1.16
mmol) and 2‐(chloromethyl)quinoline (0.622 g, 2.90 mmol) were dissolved in CHCl3 (50 mL). K2CO3
(0.883 g, 6.38 mmol) was added before being stirred to reflux overnight. The reaction mixture was washed
with water (1 x 40 mL) and extracted with HCl (0.3 M, 3 × 25 mL). The aqueous layer was recovered, and
the pH adjusted to pH 8. That layer was then extracted with CHCl3 (3 × 25 mL). The pH was further adjusted
to pH 11 and extracted with CHCl3 (6 × 25 mL). The solution was dried with Na 2SO4, filtered, and the
solvent removed under reduced pressure to give a yellow/brown oil (0.892 g, 96%). 1H NMR (CDCl3, 500
MHz): δ 2.57-2.59 (t, 4H, J = 5 MHz, NCH2CH2N), 2.68-2.69 (d, 8H, J = 5 MHz, NCH2CH2N), 2.81-2.83
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(t, 4H, J = 5 MHz, NCH2CH2N), 3.92 (s, 2H, NCH2-quin), 7.45-7.49 (td, 1H, J = 5 MHz, quin-H3), 7.587.60 (d, 1H, J = 10 MHz, quin-H6), 7.63-7.67 (td, 1H, J = 10 MHz, quin-H7), 7.74-7.76. (d, 1H, J = 10
MHz, quin-H8), 8.00-8.02 (d, 1H, J = 5 MHz, quin-H5), 8.11-8.13 (d, 1H, J = 10 MHz, quin-H4).

13C

NMR (CDCl3, 125 MHz): δ 45.13, 46.14, 46.32, 47.11, 51.91, 62.01, 120.87, 126.06, 127.46, 127.58,
128.88, 129.32, 136.67, 147.51, 160.27
2‐[4,7‐bis(carbamoylmethyl)‐10‐[(quinolin‐2‐yl)methyl]‐1,4,7,10

tetraazacyclododecan‐1‐

yl]acetamide (MP30): 2-bromoacetamide (0.516 g, 3.73 mmol), triethylamine (0.680 mL, 4.81 mmol) was
added to a solution of MP27 (0.377 g, 1.20 mmol) in acetonitrile (25 mL). The mixture was stirred to reflux
overnight. A white solid was formed, and the reaction mixture was vacuum filtered. The resulting white
solid (0.449 g, 77%) was washed with cooled acetonitrile and left to air dry. 1H NMR (D2O, 500 MHz): δ
2.28-2.43 (m, 16H, NCH2CH2N), 2.71 (s, 4H, NCH2C=O), 2.87-2.91 (m, 2H, NCH2C=O), 3.34 (s, 2H,
NCH2-quin), 7.12-7.14 (d, 1H, J = 10 MHz, quin-H3), 7.35-7.38 (m, 1H, quin-H6), 7.33-7.56 (m, 1H, quinH7), 7.64-7.66 (d, 1H, J = 10 MHz, quin-H8), 7.73-7.75 (d, 1H, J = 10 MHz, quin-H5), 7.96-7.98 (d, 1H,
J = 10 MHz, quin-H4). 13C NMR (D2O, 125 MHz): δ. 51.90, 52.27, 52.50, 56.97, 57.02, 57.15, 61.09,
121.67, 126.85, 126.99, 127.11, 127.98, 130.35, 137.64, 146.11, 158.66, 177.12, 177.29. LRMS (ESIMS): m/z calcd. for C25H37N8O3+, [M+H]+, 485.3, found 485.4; calcd. for C25H38N8O32+ [M+2H]2+, 243.2,
found 243.3; calcd. for C25H36N8NaO3+, [M+Na]+, 507.3, found 507.3.

Scheme 2-2. Synthesis of Eu-MP42
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N‐(quinolin‐2‐yl)‐2‐(1,4,7,10‐tetraazacyclododecan‐1‐yl)acetamide (M24). Cyclen (1.001 g,
5.80 mmol) and 2‐chloro‐N‐(quinolin‐2‐yl)acetamide (0.322 g, 1.45 mmol) were dissolved in CHCl 3 (25
mL). K2CO3 (0.242 g, 1.74 mmol) was added and the solution was stirred to reflux overnight. The reaction
mixture was washed with water (1 x 40 mL) and extracted with HCl (0.3 M, 3 × 25 mL). The aqueous layer
was recovered, and the pH adjusted to pH 8. The layer was then extracted with CHCl3 (3 × 25 mL). The pH
was further adjusted to pH 11 and extracted with CHCl3 (6 × 25 mL). The solution was dried with Na2SO4,
filtered, and the solvent removed under reduced pressure to give a brown solid (0.357 g, 67%). 1H NMR
(500 MHz, CDCl3):  2.66 (s, 2H, CH2NCH2), 2.70-2.72 (t, 4H, J = 5 MHz, CH2NH), 2.75-2.76 (m br, 4H,
CH2NH), 2.77 (s br, 2H, CH2NCH2), 3.00-3.01 (m br, 4H, NHCH2C-quin), 3.37 (s, 2H, CH2C=O), 7.377.39 (td, 1H, J = 5 MHz, quin-H6), 7.58-7.62 (td, 1H, J = 5 MHz, quin-H7), 7.70-7.72 (d, 1H, J = 5 MHz,
quin-H8), 7.92-7.93 (d, 1H, J = 5 MHz, quin-H3), 8.09-8.11 (d, 1H, J = 10 MHz, quin-H5), 8.41-8.43 (d,
1H, J = 10 MHz, quin-H4).

13C

NMR (125 MHz, CDCl3):  46.10, 46.96, 47.47, 48.72, 53.22, 60.54,

114.19, 124.91, 126.91, 127.29, 127.79, 129.79, 138.99, 146.99, 151.03, 171.85.
N‐(quinolin‐2‐yl)‐2‐[4,7,10‐tris(carbamoylmethyl)‐1,4,7,10‐tetraazacyclododecan‐1‐
yl]acetamide (MP42). 2-bromoacetamide (0.393 g, 2.85 mmol), triethylamine (0.520 mL, 3.67 mmol) was
added to a solution of MP24 (0.327 g, 0.918 mmol) in acetonitrile (25 mL). The mixture was stirred to
reflux overnight. A solid was formed, and the reaction mixture was vacuum filtered. The resulting white
solid (0.170 g, 35 %) was washed with cooled acetonitrile and left to air dry. 1H NMR (D2O, 500 MHz): δ
2.89-3.48 (m, 18H, NCH2CH2NCH2C=O), 3.84 (s, 2H, NCH2C-quin), 4.06-4.15 (q, 4H, J = 10 MHz,
NCH2C=O), 7.34-7.36 (d, 1H, J = 10 MHz, quin-H6), 7.68-7.70 (td, 1H, J = 5 MHz, quin-H7), 7.90-7.94
(m, 2H, quin-8 and quin-3), 8.00-8.01 (d, 1H, J = 5 MHz, quin-H5), 8.73-8.75 (d, 1H, J = 10 MHz, quinH4) 13C NMR (D2O, 125 MHz): δ 48.15, 51.72, 53.53, 54.68, 113.35, 119.28, 124.85, 128.62, 129.05,
134.19, 134.80, 147.67, 148.57, 167.90, 174.38. LRMS (ESI-MS): m/z calcd. for C25H38N9O4+ [M+H]+,
528.3, found 528.4; calcd. for C25H39N9O42+, [M+2H]2+, 264.7, found 264.8; calcd. for C25H37N9NaO4+,
[M+Na]+, 550.3, found 550.3.
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Scheme 2-3. Synthesis of Eu-MP43
N‐(quinolin‐3‐yl)‐2‐(1,4,7,10‐tetraazacyclododecan‐1‐yl)acetamide (MP38): Cyclen (1.001 g,
5.80 mmol) and 2‐chloro‐N‐(quinolin‐3‐yl)acetamide (0.319 g, 1.45 mmol) were dissolved in CHCl 3 (25
mL). K2CO3 (0.243 g, 1.74 mmol) was added and the solution was stirred to reflux overnight. The reaction
mixture was washed with water (1 x 40 mL) and extracted with HCl (0.3 M, 3 × 25 mL). The aqueous layer
was recovered, and the pH adjusted to pH 8. The layer was then extracted with CHCl3 (3 × 25 mL). The pH
was further adjusted to pH 11 and extracted with CHCl3 (6 × 25 mL). The solution was dried with Na2SO4,
filtered, and the solvent removed under reduced pressure to give a brown solid (0.460 g, 90%). 1H NMR
(500 MHz, CDCl3):  2.70-2.75 (m br, 12H, NHCH2CH2NH), 2.84-2.86 (t br, 4H, J = 5 MHz, CH2NCH2),
3.36 (s, 2H, NCH2C-quin), 7.47-7.51 (td, 1H, J = 5 MHz, quin-H6), 7.56-7.60 (td, 1H, J = 5 MHz, quinH7), 7.78-7.79 (d, 1H, J = 5 MHz, quin-H5), 7.98-7.99 (d, 1H, J = 5 MHz, quin-H8), 8.94-8.95 (d br, 1H,
J = 5 MHz, quin-H4), 9.00-9.01 (d, 1H, J = 5 MHz, quin-H2). 13C NMR (125 MHz, CDCl3):  46.11, 46.17,
47.46, 47.61, 53.93, 59.94, 122.89, 126.94, 127.81, 127.85, 128.39, 128.83, 132.15, 144.60, 144.93, 171.30.
N‐(quinolin‐3‐yl)‐2‐[4,7,10‐tris(carbamoylmethyl)‐1,4,7,10‐tetraazacyclododecan‐1‐
yl]acetamide (MP43): 2-bromoacetamide (0.525 g, 3.79 mmol), triethylamine (0.682 mL, 4.90 mmol) was
added to a solution of MP38 (0.436 g, 1.22 mmol) in acetonitrile (25 mL). The mixture was stirred to reflux
overnight. A solid was formed, and the reaction mixture was vacuum filtered. The resulting tan solid (0.349
g, 54 %) was washed with cooled acetonitrile and left to air dry. 1H NMR (D2O, 500 MHz): δ 2.86-3.59
(m, 22H, NCH2CH2N and CH2CH2C=O), 4.00 (s br, 2H, NCH2C-quin), 7.50-7.53 (m, 1H, quin-H6), 7.627.65 (m, 1H, quin-H7), 7.69-7.71 (d, 1H, J = 10 MHz, quin-H5), 7.76-7.77 (d, 1H, J = 5 MHz, quin-H8),
8.32 (s br, 1H, quin-H4), 8.67-8.68 (d, 1H, J = 5 MHz, quin-H2) 13C NMR (D2O, 125 MHz): δ 48.45,
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51.42, 54.35, 54.55, 54.98, 57.36, 124.84, 127.81, 127.93, 128.06, 128.42 130.56, 131.52, 140.54, 141.89,
167.33, 168.00. LRMS (ESI-MS): m/z calcd. for C25H38N9O4+, [M+H]+, 528.3, found 528.4; calcd. for
C25H39N9O42+, [M+2H]2+, 264.7, found 264.8; calcd. for C25H37N9NaO4+, [M+Na]+, 550.3, found 550.3.

Scheme 2-4. Synthesis of Eu-MP44
N‐(quinolin‐4‐yl)‐2‐(1,4,7,10‐tetraazacyclododecan‐1‐yl)acetamide (MP25): Cyclen (1.001 g,
5.80 mmol) and 2‐chloro‐N‐(quinolin‐4‐yl)acetamide (0.320 g, 1.45 mmol) were dissolved in CHCl 3 (25
mL). K2CO3 (0.245 g, 1.74 mmol) was added and the solution was stirred to reflux overnight. The reaction
mixture was washed with water (1 x 40 mL) and extracted with HCl (0.3 M, 3 × 25 mL). The aqueous layer
was recovered, and the pH adjusted to pH 8. The layer was then extracted with CHCl3 (3 × 25 mL). The pH
was further adjusted to pH 11 and extracted with CHCl3 (6 × 25 mL). The solution was dried with Na2SO4,
filtered, and the solvent removed under reduced pressure to give a brown solid (0.399 g, 77%). 1H NMR
(500 MHz, CDCl3):  2.67-2.81 (m, 16H, NHCH2CH2NH), 3.41 (s, 2H, NCH2C-quin), 7.50-7.54 (td, 1H,
J = 5 MHz, quin-H3), 7.66-7.69 (td, 1H, J = 5 MHz, quin-H7), 8.05-8.07 (d, 1H, J = 10 MHz, quin-H6),
8.34-8.35 (d, 1H, J = 5 MHz, quin-H8), 8.40-8.42 (d, 1H, J = 10 MHz, quin-H5), 8.81-8.82 (d, 1H, J = 5
MHz, quin-H2). 13C NMR (125 MHz, CDCl3):  46.07, 47.30, 47.38, 53.92, 60.87, 110.83, 120.39, 121.19,
126.03, 129.27, 130.10, 140.73, 149.01, 151.20, 171.02.
N‐(quinolin‐4‐yl)‐2‐[4,7,10‐tris(carbamoylmethyl)‐1,4,7,10‐tetraazacyclododecan‐1‐
yl]acetamide (MP44): 2-bromoacetamide (0.460 g, 3.32 mmol), triethylamine (0.600 mL, 4.29 mmol) was
added to a solution of MP25 (0.382 g, 1.07 mmol) in acetonitrile (25 mL). The mixture was stirred to reflux
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overnight. A solid was formed, and the reaction mixture was vacuum filtered. The resulting white solid
(0.408 g, 72 %) was washed with cooled acetonitrile and left to air dry. 1H NMR (D2O, 500 MHz): δ 2.903.12 (m, 18H, NCH2CH2NCH2C=O), 3.87 (s br, 2H, NCH2C-quin), 4.09 (s br, 4H, NCH2C=O), 7.57-7.60
(m, 1H, quin-H3), 7.83-7.86 (m, 1H, quin-H7), 7.92-7.93 (d, 1H, J = 5 MHz, quin-H6), 8.04-8.05 (d, 1H, J
= 5 MHz, quin-H8), 8.21-8.22 (d, 1H, J = 5 MHz, quin-H5), 8.56-8.57 (d, 1H, J = 5 MHz, quin-H2). 13C
NMR (D2O, 125 MHz): δ 48.33, 51.64, 54.27, 54.58, 55.50, 57.36, 110.43, 119.51, 122.04, 122.14, 128.72,
133.87, 139.99, 145.36, 147.81, 168.19, 172.42. LRMS (ESI-MS): m/z calcd. for C25H38N9O4+, [M+H]+,
528.3, found 528.4; calcd. for C25H39N9O42+, [M+2H]2+, 264.7, found 264.9; calcd. for C25H37N9NaO4+,
[M+Na]+, 550.3, found 550.4.

Scheme 2-5. Synthesis of Eu-MP45
N‐(quinolin‐5‐yl)‐2‐(1,4,7,10‐tetraazacyclododecan‐1‐yl)acetamide (MP40): Cyclen (1.001 g,
5.80 mmol) and 2‐chloro‐N‐(quinolin‐5‐yl)acetamide (0.319 g, 1.45 mmol) were dissolved in CHCl 3 (25
mL). K2CO3 (0.241 g, 1.74 mmol) was added and the solution was stirred to reflux overnight. The reaction
mixture was washed with water (1 x 40 mL) and extracted with HCl (0.3 M, 3 × 25 mL). The aqueous layer
was recovered, and the pH adjusted to pH 8. The layer was then extracted with CHCl3 (3 × 25 mL). The pH
was further adjusted to pH 11 and extracted with CHCl3 (6 × 25 mL). The solution was dried with Na2SO4,
filtered, and the solvent removed under reduced pressure to give a pink solid (0.500 g, 96%). 1H NMR (500
MHz, CDCl3): 2.66-2.80 (m, 16H, NHCH2CH2NH), 3.45 (s, 2H, NCH2C-quin), 7.39-7.42 (q, 1H, J = 5
MHz, quin-H3), 7.68-7.71 (m, 1H, quin-H6), 7.92-7.94 (d, 1H, J = 10 MHz, quin-H7), 8.05-8.07 (d, 1H, J
= 10 MHz, quin-H8), 8.69-8.71 (d, 1H, J = 10 MHz, quin-H4), 8.89-8.91 (dd, 1H, J = 5 MHz, quin-H2).
13C

NMR (125 MHz, CDCl3):  46.09, 46.13, 47.23, 47.46, 60.34, 120.46, 120.67, 122.50, 126.68, 129.35,

131.10, 133.07, 148.68, 150.30, 170.83.
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N‐(quinolin‐5‐yl)‐2‐[4,7,10‐tris(carbamoylmethyl)‐1,4,7,10‐tetraazacyclododecan‐1‐
yl]acetamide (MP45): 2-bromoacetamide (0.586 g, 4.25 mmol), triethylamine (0.770 mL, 5.48 mmol) was
added to a solution of MP40 (0.488 g, 1.37 mmol) in acetonitrile (20 mL). The mixture was stirred to reflux
overnight. A solid was formed, and the reaction mixture was vacuum filtered. The resulting yellow solid
(0.474 g, 66 %) was washed with cooled acetonitrile and left to air dry. 1H NMR (D2O, 500 MHz): δ 2.462.63 (m, 16H, NCH2CH2N), 2.90-2.93 (d, 6H, J = 15 MHz, NCH2C=O), 3.24 (s, 2H, NCH2C-quin), 7.367.38 (m, 2H, quin-H3 and H6), 7.60-7.63 (m, 1H, quin-H7), 7.80-7.81 (d, 1H, J = 5 MHz, quin-H8), 8.048.06 (d, 1H, J = 10 MHz, quin-H4), 8.67 (s, 1H, quin-H2). 13C NMR (D2O, 125 MHz): δ 52.24, 52.43,
56.87, 57.14, 57.33, 58.17, 121.79, 124.22, 124.52, 124.58, 127.17, 129.74, 131.80, 132.18, 146.97, 147.00,
150.47, 173.64, 176.78. LRMS (ESI-MS): m/z calcd. for C25H38N9O4+, [M+H]+, 528.3, found 528.4; calcd.
for C25H39N9O42+, [M+2H]2+, 264.7, found 264.8; calcd. for C25H37N9NaO4+, [M+Na]+, 550.3, found 550.3.

Scheme 2-6. Synthesis of Eu-MP46
N‐(quinolin‐6‐yl)‐2‐(1,4,7,10‐tetraazacyclododecan‐1‐yl)acetamide (MP39): Cyclen (1.000 g,
5.80 mmol) and 2‐chloro‐N‐(quinolin‐6‐yl)acetamide (0.319 g, 1.45 mmol) were dissolved in CHCl 3 (25
mL). K2CO3 (0.242 g, 1.74 mmol) was added and the solution was stirred to reflux overnight. The reaction
mixture was washed with water (1 x 40 mL) and extracted with HCl (0.3 M, 3 × 25 mL). The aqueous layer
was recovered, and the pH adjusted to pH 8. The layer was then extracted with CHCl3 (3 × 25 mL). The pH
was further adjusted to pH 11 and extracted with CHCl3 (6 × 25 mL). The solution was dried with Na2SO4,
filtered, and the solvent removed under reduced pressure to give a brown solid (0.467 g, 90%). 1H NMR
(500 MHz, CDCl3):  2.69-2.75 (m, 12H, NHCH2CH2NH), 2.83-2.85 (t br, 4H, J = 5 MHz,
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NHCH2CH2NH), 3.33 (s, 2H, NCH2C-quin), 7.32-7.35 (q, 1H, J = 5 MHz, quin-H3), 7.79-7.82 (dd, 1H, J
= 5 MHz, quin-H7), 7.98-8.00 (d, 1H, J = 10 MHz, quin-H5), 8.09-8.11 (d br, 1H, J = 10 MHz, quin-H8),
8.51-8.52 (d, 1H, J = 5 MHz, quin-H4), 8.77-8.79 (dd, 1H, J = 5 MHz, quin-H2). 13C NMR (125 MHz,
CDCl3):  45.88, 46.08, 47.27, 47.28, 53.77, 59.79, 115.50, 121.41, 123.30, 128.86, 129.95, 135.84, 136.34,
145.43, 149.10, 170.59.
N‐(quinolin‐6‐yl)‐2‐[4,7,10‐tris(carbamoylmethyl)‐1,4,7,10‐tetraazacyclododecan‐1‐
yl]acetamide (MP46): 2-bromoacetamide (0.535 g, 3.87 mmol), triethylamine (0.700 mL, 5.00 mmol) was
added to a solution of MP39 (0.445 g, 1.25 mmol) in acetonitrile (20 mL). The mixture was stirred to reflux
overnight. A solid was formed, and the reaction mixture was vacuum filtered. The tan solid (0.427 g, 65 %)
was washed with cooled acetonitrile and left to air dry. 1H NMR (D2O, 500 MHz): δ 2.93-3.50 (m br, 18H,
NCH2CH2NCH2C=O), 3.66 (s br, 2H, NCH2C-quin), 4.06 (s br, 4H, NCH2C=O), 7.86-7.89 (m, 1H, quinH3), 7.94 (s br, 1H, quin-H7), 8.01 (s br, 1H, quin-H5), 8.32 (s br, 1H, quin-H8), 8.80 (s br, 1H, quin-H4),
8.85-8.86 (d, 1H, J = 5 MHz, quin-H2). 13C NMR (D2O, 125 MHz): δ 48.47, 51.46, 54.52, 54.71, 55.26,
57.35, 110.12, 116.52, 121.01, 122.04, 128.83, 129.60, 134.38, 138.36, 142.63, 146.64, 167.46. LRMS
(ESI-MS): m/z calcd. for C25H38N9O4+, [M+H]+, 528.3, found 528.4; calcd. for C25H39N9O42+, [M+2H]2+,
264.7, found 264.9; calcd. for C25H37N9NaO4+, [M+Na]+, 550.3, found 550.3.

Scheme 2-7. Synthesis of Eu-MP47
N‐(quinolin‐7‐yl)‐2‐(1,4,7,10‐tetraazacyclododecan‐1‐yl)acetamide (MP26): Cyclen (1.001 g,
5.80 mmol) and 2‐chloro‐N‐(quinolin‐7‐yl)acetamide (0.321 g, 1.45 mmol) were dissolved in CHCl 3 (25
mL). K2CO3 (0.241 g, 1.74 mmol) was added and the solution was stirred to reflux overnight. The reaction
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mixture was washed with water (1 x 40 mL) and extracted with HCl (0.3 M, 3 × 25 mL). The aqueous layer
was recovered, and the pH adjusted to pH 8. The layer was then extracted with CHCl3 (3 × 25 mL). The pH
was further adjusted to pH 11 and extracted with CHCl3 (6 × 25 mL). The solution was dried with Na2SO4,
filtered, and the solvent removed under reduced pressure to give a brown solid (0.357 g, 67%). 1H NMR
(500 MHz, CDCl3):  2.69-2.85 (m, 16H, NHCH2CH2NH), 3.32 (s, 2H, NCH2C-quin), 7.24-7.27 (q, 1H, J
= 5 MHz, quin-H3), 7.70-7.72 (d, 1H, J = 10 MHz, quin-H6), 8.02-8.04 (d br, 1H, J = 10 MHz, quin-H8),
8.11-8.14 (dd, 1H, J = 5 MHz, quin-H4), 8.28-8.29 (dd, 1H, J = 5 MHz, quin-H5), 8.80-8.82 (dd, 1H, J =
5 MHz, quin-H2).

13C

NMR (125 MHz, CDCl3):  45.88, 47.04, 47.15, 53.73, 59.85, 116.77, 119.81,

120.51, 125.11, 128.39, 135.63, 139.63, 148.78, 150.71, 170.64.
N‐(quinolin‐7‐yl)‐2‐[4,7,10‐tris(carbamoylmethyl)‐1,4,7,10‐tetraazacyclododecan‐1‐
yl]acetamide (MP47): 2-bromoacetamide (0.699 g, 5.03 mmol), triethylamine (0.905 mL, 6.49 mmol) was
added to a solution of MP26 (0.578 g, 1.62 mmol) in acetonitrile (20 mL). The mixture was stirred to reflux
overnight. A solid was formed, and the reaction mixture was vacuum filtered. The resulting orange solid
(0.4786 g, 56 %) was washed with cooled acetonitrile and left to air dry. 1H NMR (D2O, 500 MHz): δ 2.863.62 (m, 22H, NCH2CH2NCH2C=O), 4.02 (s br, 2H, NCH2C-quin), 7.60-7.62 (d, 1H, J = 10 MHz, quinH3), 7.72-7.74 (t, 1H, J = 5 MHz, quin-H6), 7.99-8.01 (d, 1H, J = 10 MHz, quin-H8), 8.37 (s, 1H, quinH4), 8.79-8.81 (d, 2H, J = 10 MHz, quin-H5 and quin-H2). 13C NMR (D2O, 125 MHz): δ 48.51, 51.46,
54.51, 54.84, 55.30, 57.34, 106.86, 120.07, 123.47, 126.01, 130.16, 138.58, 143.24, 143.71, 146.71, 167.95,
171.67. LRMS (ESI-MS): m/z calcd. for C25H38N9O4+, [M+H]+, 528.3, found 528.4; calcd. for
C25H39N9O42+, [M+2H]2+, 264.7, found 264.9; calcd. for C25H37N9NaO4+, [M+Na]+, 550.3, found 550.4.

Scheme 2-8. Synthesis of Eu-MP48
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N‐(quinolin‐8‐yl)‐2‐(1,4,7,10‐tetraazacyclododecan‐1‐yl)acetamide (MP41): Cyclen (1.000 g,
5.80 mmol) and 2‐chloro‐N‐(quinolin‐8‐yl)acetamide (0.322 g, 1.45 mmol) were dissolved in CHCl 3 (25
mL). K2CO3 (0.242 g, 1.74 mmol) was added and the solution was stirred to reflux overnight. The reaction
mixture was washed with water (1 x 40 mL) and extracted with HCl (0.3 M, 3 × 25 mL). The aqueous layer
was recovered, and the pH adjusted to pH 8. The layer was then extracted with CHCl3 (3 × 25 mL). The pH
was further adjusted to pH 11 and extracted with CHCl3 (6 × 25 mL). The solution was dried with Na2SO4,
filtered, and the solvent removed under reduced pressure to give a white solid (0.380 g, 74%). 1H NMR
(500 MHz, CDCl3):  2.68-2.78 (m, 13H, NHCH2CH2NH), 2.85-2.87 (t, 3H, J = 5 MHz, NHCH2CH2NH),
3.39 (s, 2H, NCH2C-quin), 7.38-7.41 (q, 1H, J = 5 MHz, quin-H7), 7.38-7.51 (m, 2H, quin-H3 and quinH5), 8.09-8.11 (dd, 1H, J = 10 MHz, quin-H6), 8.74-8.75 (dd, 1H, J = 5 MHz, quin-H4), 8.85-8.86 (dd,
1H, J = 5 MHz, quin-H2), 11.05 (s, 1H, NH). 13C NMR (125 MHz, CDCl3):  45.30, 45.52, 46.09, 46.76,
52.94, 61.84, 116.85, 121.45, 121.81, 127.19, 128.14, 134.12, 136.22, 138.89, 148.42, 169.76.
N‐(quinolin‐8‐yl)‐2‐[4,7,10‐tris(carbamoylmethyl)‐1,4,7,10‐tetraazacyclododecan‐1‐
yl]acetamide (MP48): 2-bromoacetamide (0.420 g, 3.04 mmol), triethylamine (0.550 mL, 3.92 mmol) was
added to a solution of MP41 (0.349 g, 0.980 mmol) in acetonitrile (20 mL). The mixture was stirred to
reflux overnight. A solid was formed, and the reaction mixture was vacuum filtered. The resulting white
solid (0.375 g, 73%) was washed with cooled acetonitrile and left to air dry. 1H NMR (D2O, 500 MHz): δ
3.14-3.32 (m br, 18H, NCH2CH2NCH2C=O), 3.87 (s br, 6H, NCH2C-quin), 7.48 (s br, 2H, quin-H7 and
quin-H3), 7.65 (s br, 1H, quin-H5), 8.05-8.06 (d, 1H, J = 5 MHz, quin-H6), 8.26 (s br, 1H, quin-H4), 8.70
(s, 1H, quin-H2). 13C NMR (D2O, 125 MHz): δ 49.32, 50.70, 54.46, 54.99, 55.09, 57.36, 122.07, 122.30,
125.35, 126.98, 128.48, 131.74, 138.52, 138.77, 149.23 167.26, 169.29. LRMS (ESI-MS): m/z calcd. for
C25H38N9O4+, [M+H]+, 528.3, found 528.4; calcd. for C25H39N9O42+, [M+2H]2+, 264.7, found 264.9; calcd.
for C25H37N9NaO4+, [M+Na]+, 550.3, found 550.3.

Metal Complexation
Each ligand was dissolved in H2O (7 mL) and the pH of the solution adjusted to 6 using 0.3 M HCl.
Equimolar amounts of aqueous EuCl3 was added, and the solution was stirred at room temperature
overnight. The pH was raised to 10 by addition of 0.3 M NaOH to precipitate excess Eu3+ as Eu(OH)3. The
precipitate was removed by syringe filtration, and the absence of free metal was confirmed using a Xylenol
Orange test. The pH of the solution was adjusted to 7 and lyophilized to yield a solid.
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[Eu-MP30]: White solid. LRMS (ESI-MS): m/z calcd. for C24H36EuN8O32+, M2+, 318.6, found
318.3.

[Eu-MP42]: White solid. LRMS (ESI-MS): m/z calcd. for C25H37EuN9Na2O45+, [M3+ + 2Na]5+,
145.2, found 145.2; calcd. for C25H37EuN9O43+, M3+, 226.7, found 227.0.

[Eu-MP43]: Light golden tan solid, quantitative yield. LRMS (ESI-MS): m/z calcd. for
C25H37EuKN9O43+, [M2+ + K]3+, 239.7, found 239.3; calcd. for C25H37EuN9O43+, M3+, 226.7, found 227.0.

[Eu-MP44]: White solid, quantitative yield. LRMS (ESI-MS): m/z calcd. for C25H37EuN9Na2O45+,
[M3+ + 2Na]5+, 145.2, found 145.2; calcd. for C25H37EuKN9O43+, [M2+ + K]3+, 239.7, found 239.3.

[Eu-MP45]: Golden brown solid. LRMS (ESI-MS): m/z calcd. for C25H37EuKN9O43+, [M2+ + K]3+,
239.7, found 239.3; calcd. for C25H37EuN9O43+, M3+, 226.7, found 227.0.

[Eu-MP46]: Golden brown solid. LRMS (ESI-MS): m/z calcd. for C25H37EuKN9O43+, [M2+ + K]3+,
239.7, found 239.3; calcd. for C25H37EuN9O43+, M3+, 226.7, found 227.0.

[Eu-MP47]: Golden brown solid. LRMS (ESI-MS): m/z calcd. for C25H37EuKN9O43+, [M2+ + K]3+,
239.7, found 239.3; calcd. for C25H37EuN9O43+, M3+, 226.7, found 227.0.

[Eu-MP48]: Light gold solid. LRMS (ESI-MS): m/z calcd. for C25H37EuN9O43+, M3+, 226.7, found
227.0; calcd. for C25H37EuKN9O43+, [M2+ + K]3+, 239.7, found 239.3.

Absorbance Measurements
Absorbance spectra were acquired at room temperature over a 200-800 nm range using a 1.0 cm
quartz cuvette and a 5 nm slit. Solutions of each lanthanide complex were prepared at 0.00625 mM in 0.1
mM HEPES buffer (pH 7.4).

Acquisition of Emission Spectra
Solutions of each lanthanide complex were prepared at 0.1 mM using 0.1 mM HEPES buffer (pH
7.4). A 450 nm long pass filter was used to eliminate second order peaks. Spectra were recorded at room
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temperature using a 1.0 cm quartz cell and an excitation monochromator slit width of 2 nm. Emission
spectra were acquired from 570-750 nm. Each complex was excited at the maximum ex (Table 3).
Table 2-1. Excitation wavelengths of each compound
Compound
Eu-MP30
Eu-MP42
ex (nm)
319
325
Compound
ex (nm)

Eu-MP45
314

Eu-MP46
325

Eu-MP43
328

Eu-MP44
354

Eu-MP47
326

Eu-MP48
312

Acquisition of Excitation Spectra
Solutions of each lanthanide complex were prepared at 0.1 mM using 0.1 mM HEPES buffer (pH
7.4). A 450 nm long pass filter was used to eliminate second order peaks. Spectra were recorded at room
temperature using a 1.0 cm quartz cell and an emission monochromator slit width of 2 nm. Excitation
spectra of all complexes were acquired from 200-450 nm. Each spectrum was acquired with the em
indicated in Table 4.

Table 2-2. Emission wavelengths of each compound
Compound

Eu-MP30

Eu-MP42

Eu-MP43

Eu-MP44

em (nm)

636

635

635

635

Compound
em (nm)

Eu-MP45
635

Eu-MP46
634

Eu-MP47
634

Eu-MP48
635

Lifetime Measurements
Phosphorescence decay by delay measurements were acquired using a flash count of 50, sample
window of 0.2 ms, 0.05 ms delay increment, 5 ms max delay, and an initial delay of 0.05 ms. Samples were
prepared by lyophilizing aliquots of each lanthanide solution in 500 L of 0.1 mM HEPES buffer (pH 7.4).
One aliquot of each lanthanide solution was then redissolved in D2O and lyophilized. These samples were
dissolved once more in D2O and lyophilized. Solutions at 0.02 mM concentration were made by dissolving
the compounds in HEPES buffer or D2O. The data was fit with a mono-exponential decay function to obtain
 values. The number of bound water molecules (q) was determined using equation 1 where x represents
the number of amide protons in each complex.24
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𝑞𝐸𝑢 = 1.2[(𝑘𝐻2 𝑂 − 𝑘𝐷2𝑂 ) − 0.25 − 0.075𝑥]

(1)

Quantum Yield ( ) Measurements
Absorbance spectra were acquired over a 200-800 nm range and at room temperature, using a 1.0
cm quartz cuvette and a 5 nm slit width. Solutions of each lanthanide complex were prepared using 0.1 mM
HEPES buffer (pH 7.4) such that their absorbance intensities at 315 nm fell between 0.005 and 0.05.
Emission spectra were acquired upon excitation at 315 nm from 570-750 nm. Areas under the emission
curves versus absorbance intensities at 315 nm were graphed and fit with a linear equation. These plots
were compared with data acquired in a similar manner for reference compounds with known quantum yields
[Rhodamine 101 in ethanol ( = 1)].25 Equation 2 was used to determine the quantum yield value of each
complex where R denotes values corresponding to the reference compound, x corresponds to the unknown
sample measurements, m represents the slope from the linear fit of the area under the emission curve versus
absorbance intensity, and n is the refractive index of the solvent used.26
𝑚

𝑛

Φ𝑥 = Φ𝑅 (𝑚𝑥 )(𝑛𝑥 )2
𝑅

𝑅

(2)

Kinetic Stability Measurements
Each complex was diluted to 0.1 mM with 10 mM citrate buffer at pH 3 and stored in a quartz
cuvette at 21 oC and in a hot water bath at 37 oC. The emission intensities at 615 nm were monitored over
7 days at 21 oC, and over 48 h at 37 oC. The resulting emission data was plotted as a function of time and
fit to a monoexponential decay function to estimate the emission decay half-life for each compound.
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2.3 Results and Discussion
Absorption Properties
Absorption spectra were acquired for each complex to evaluate how differences in the quinoline
antenna affect the photophysical properties of the library of Eu3+ complexes. To this end, absorption in the
250-350 nm range was analyzed as this is the region in which  → * and n → * transitions are typically
observed for quinoline compounds.27,28 Normalized absorption spectra for all complexes are shown in
Figure 2-4.

Eu-MP30

1.0

Absorbance

Eu-MP42
Eu-MP43
Eu-MP44
Eu-MP45

0.5

Eu-MP46
Eu-MP47
Eu-MP48

0.0
250

275

300

325

350

Wavelength (nm)
Figure 2-4. Normalized absorbance spectra of 0.0625 mM solutions of each complex prepared in 0.1 mM
HEPES buffer (pH 7.4). Spectra were obtained at room temperature from 200-800 nm.

The absorption spectra of all compounds in this study exhibit similar broad peaks, with the lowest
energy peaks between 300 and 340 nm. These peaks can be attributed to  → * transitions for the quinoline
side-chains.28 The max values are slightly different for each compound. This suggests that changes in the
positions of the amide substituents relative to the quinoline nitrogen do affect the maximum energy that can
be absorbed by the quinoline antenna.

Analysis of Excitation Spectra
Through acquisition of the excitation spectra, one can evaluate the amount of energy required to
excite an electron from the singlet ground state to the singlet excited state on the quinoline chromophore. 6
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Following intersystem crossing from the singlet excited state to the triplet excited state of the ligand, some
of the energy absorbed by the ligand will be transferred to the Ln3+ excited states. The sharp emission lines
from the metal center are typically observed following rapid internal conversion to the emitting level of the
lanthanide ion.7 The excitation spectra for all complexes can be found in Figure 2-5.
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Figure 2-5. Normalized excitation spectra of all complexes prepared at 0.1 mM with 0.1 mM HEPES
buffer (pH 7.4). Spectra were acquired at room temperature from 200-450 nm with an emission
monochromator slit width of 2 nm. em values used to acquire each spectrum and maximum wavelengths
of excitation can be found in Table 2-3.

Table 2-3. Peak emission and excitation wavelengths of each complex ( 2 nm).
Complex
Eu-MP30
Eu-MP42
Eu-MP43
Eu-MP44
Eu-MP45
Eu-MP46
Eu-MP47
Eu-MP48

em
636
635
635
635
635
634
634
635

ex
319
325
328
354
314
325
326
312

The maximum excitation wavelengths are reflective of  → * electronic transitions in each ligand
and vary from largest energy (312 nm) for Eu-MP48 to smallest energy (354 nm) for Eu-MP44.28 There
may be slightly higher conjugation in Eu-MP44 brought about by the quinoline amide being in the para-
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substituted position relative to the nitrogen atom in the ring. The para position allows for overlap between
the p-orbitals of nitrogen on the quinoline ring and the amide substituted carbon. The overlap between these
orbitals leads to a higher conjugation of the molecule, which allows for a greater delocalization of the
electrons.29 The higher conjugation of this compound leads to a smaller energy gap between the →*
electronic transition. The smaller energy gap results in a longer wavelength due to the relationship between
energy and wavelength. This means that lower energy is required to promote electrons from the singlet
ground to singlet excited state of the ligand.30

Evaluation of Emission Properties
The emission spectra of all complexes display characteristic Eu3+ centered emission properties
(Figure 2-6). Narrow emission bands from 5D0 – 7FJ,where J = 0 – 4, are observed between 598 – 717 nm,
with the most intense emission band located at approximately 615 nm.31
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Figure 2-6. Emission spectra of 0.1 mM complexes prepared in 0.1 mM HEPES buffer (pH 7.4). Spectra
were acquired at room temperature from 570-750 nm with an excitation monochromator slit width of 2
nm. ex values can be found in Table 2-3.

Eu-MP30 possessed the highest emission intensity of all compounds. A shortened distance between
the directly coordinated quinoline chromophore and the lanthanide center could allow for more efficient
sensitization of the lanthanide’s luminescence.3 All other complexes displayed emission intensities that
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varied based on the location of the amide on the quinoline sidearm, with Eu-MP42 having the highest
emission intensity and Eu-MP48 having the lowest intensity. The difference in amide substituent location
on the quinoline antenna may result in increased rigidity of some of the compounds. Increased rigidity could
potentially minimize energy loss via X-H vibrations, which could result in an increase in emission intensity
due to reduced quenching.15 Another potential cause for the differences in emission intensity may lie in the
mechanism for sensitizing the lanthanide ion through pendant antenna, the Förster resonance energy
transfer.10 This mechanism is reliant on the dipole-dipole coupling between the longitudinal relaxation of
the antenna and the energy of the 4f orbitals of the lanthanide, and depends upon the distance r between the
antenna and the lanthanide ion, with an efficiency 1/r6. It is possible that the changes in the location of the
amide substituent impacts the energy transfer mechanism by altering the distance between the europium
ion and the quinoline antenna, thus resulting in a change in emission intensity.

The emission bands in a Eu3+ spectrum can also be used to draw conclusions about the symmetry
of the compound. In particular, the J = 0 and J = 2 bands at 590 nm and 615 nm, respectively, can indicate
structural properties.8 The J = 0 band located at approximately 590 nm is typically a weak, forbidden band
in most Eu3+ complexes as explained by the Judd-Ofelt theory.8 This band can be seen at a relatively high
intensity in all of the metal complexes. This sharp appearance of the J = 0 emission band implies that the
Eu3+ ion occupies a site with Cnv, Cn, or Cs symmetry.8 The J = 2 band at 615 nm is known as the
hypersensitive transition, and its intensity is also heavily influenced by the local symmetry of the lanthanide
ion.32,33 Higher asymmetry of the complex leads to a higher emission intensity.34,35 Higher asymmetry of
the ligand field makes the forbidden f-f transitions somewhat more allowed by modifying the interaction
between the inner 4f-shell of the Eu3+ ion with its environment.36,37 Asymmetry enhances the luminescence
of the complex by reducing the nonradiative decay rate and increasing the probability of radiative
emission.38 The ratio of the intensities between this band and the J = 1 band are used to measure the
asymmetry of the Eu3+ site. The higher the intensity ratio, the more asymmetric the metal complex.8 These
ratios are summarized in Table 2-4.

Eu-MP30, Eu-MP43, Eu-MP46, and Eu-MP47 have the same ratio which indicates these
complexes have very similar symmetry. Eu-MP44 has the highest ratio of 1.87 and therefore is assumed to
have the most asymmetry of all the compounds. Although this does not seem to impact its emission intensity
as the intensity of Eu-MP44 falls between those of the other compounds, but it may be responsible for the
lower energy of excitation. Eu-MP45 and Eu-MP48 have the lowest intensity ratios, showing these
compounds are more symmetric than the other Eu3+ complexes. The higher symmetry of these complexes
corresponds to the low emission intensity of both compounds.
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Table 2-4. Ratio of intensities of the J = 1 and J = 2 bands of the Eu3+ emission spectra.
J = 1 Intensity
3050000
1210000
757800
669280
182950
1120000
1180000
36340

Compound
Eu-MP30
Eu-MP42
Eu-MP43
Eu-MP44
Eu-MP45
Eu-MP46
Eu-MP47
Eu-MP48

J = 2 Intensity
3860000
1680000
964210
1250000
298500
1420000
1490000
42930

Area Under Emission Curve

2×108
2×10

800000

Chromophore Excitation
Lanthanide Excitation

8

Ratio I2/I1
1.27
1.39
1.27
1.87
1.08
1.27
1.26
1.18
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Figure 2-7. Comparison of areas under the emission spectra upon excitation of the quinoline antenna
(blue) and direct excitation of the lanthanide ion at ex = 395 nm (red). Inset: Magnified view of the data
for Eu-MP48.

Free lanthanide ions on their own do not display adequate luminescent capabilities due to forbidden
4f-4f transitions and low molar absorptivity coefficients ( < 1 M-1cm-1).10,39 To overcome this limitation,
an organic chromophore (antenna) is typically used to aid in the sensitization of the lanthanide’s
luminescence. Figure 2-7 shows a comparison of the emission intensities upon excitation of the antenna on
the ligand versus direct excitation of the Eu3+ ion. For all compounds, excitation of the quinoline antenna
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results in 2 – 10000-fold higher emission intensities compared to direct excitation of the lanthanide ion.
Even Eu-MP48, with the lowest emission intensity overall, displays a 2-fold increase in the magnitude of
the emission intensity in comparison to direct excitation of the Eu3+ ion. This indicates that antenna
sensitization of the Eu3+ ion occurred regardless of the identity of the quinoline amide side-chain.

Figure 2-8. From left to right, Eu-MP30, Eu-MP42, Eu-MP43, Eu-MP44, Eu-MP45, Eu-MP46, EuMP47, and Eu-MP48 (1E-4 M) in 0.1 M MES buffer (pH 7.5). All compounds were excited using a UV
light source at 302 nm except Eu-MP44 that was excited at 365 nm.

Upon irradiation with a UV lamp, most compounds display the red color characteristic of Eu 3+
complexes (Figure 2-8), and it is visible to the naked eye. Excitation at 365 nm is not optimal for all of the
complexes, thus the brightness observed does not directly correlate with the measured emission intensity
(Figure 2-6). However, all complexes aside from Eu-MP48 and Eu-MP45 emit red light upon excitation at
this longer wavelength. The ability to excite the complexes at longer wavelength allows for the use of lower
energy

light

sources

which

will

potentially

be

less

damaging

to

biological

tissue.

Determination of Quantum Yield Values
Quantum yield is a measure of the ratio of emitted photons to absorbed photons.40 It is therefore a
measurement of the probability that an excited photon will emit light as it relaxes to equilibrium. The overall
quantum yield also takes into account the energy transfer efficiency from the antenna to the lanthanide ion.
Quantum yields were determined using previously published methods.26 The calculated quantum yield
values for each complex can be found in Table 2-5.
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Table 2-5. Calculated quantum yield and brightness values of Eu3+ complexes prepared in 0.1 mM
HEPES buffer (pH 7.4) using Rhodamine 101 in ethanol ( = 1)25 as a reference at 315 nm.
Compound

Quantum Yield ()

Eu-MP30
Eu-MP42
Eu-MP43
Eu-MP44
Eu-MP45
Eu-MP46
Eu-MP47
Eu-MP48

0.0272
0.0040
0.0043
0.0028
0.0022
0.0091
0.0105
0.0005

Molar Absorptivity
Coefficient () (M-1 cm-1)
7160
5100
5730
5070
7650
2910
5210
5460

Calculated B
195
20.4
24.6
14.2
16.8
26.5
54.7
2.73

Eu-MP30, the complex with the directly coordinated quinoline sidearm, exhibited the highest
quantum yield of all synthesized complexes. This is attributed to the close distance between the quinoline
antenna and the lanthanide center allowing for better sensitization of the lanthanide ion’s luminescence
through the Förster mechanism.9 This observation was also consistent with Eu-MP30 displaying the highest
emission intensity. Eu-MP48 exhibited the lowest quantum yield, and this was well correlated to its very
low emission intensity. The quantum yields of all compounds in this study ranged from 0.05 – 2.72%.
Previous studies on Eu3+ complexes have reported similar quantum yield values, with compounds
containing directly coordinated antennae having quantum yields of 3.9 – 6%, and those with indirectly
coordinated antennae yielding values of 1.4 – 6.2%.41,42
In the development of agents for optical imaging of biological tissue, it is important to design
compounds with high quantum yields. This helps to ensure adequate brightness of the agent, which is
important for proper visualization of tissue. The relationship between brightness and quantum yield is
shown in equation 3 where  is the molar absorptivity coefficient of the antenna and  is the luminescence
quantum yield.43 This direct relationship between brightness and quantum yield supports the correlation
between the low quantum yields calculated for Eu-MP48 and Eu-MP45 and visible brightness. Calculated
brightness values can be found in Table 2-5.
𝐵 = 𝜀Φ

(3)

Singlet and Triplet State Energies
As previously mentioned, enhanced sensitization of the luminescence of the Eu3+ ions involves the
transfer of energy from the triplet excited state of the chromophore to the metal center. Following rapid
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internal conversion to the emitting level of the lanthanide, light is emitted as sharp emission bands
characteristic of Eu3+.6,7,8 For efficient energy transfer to occur, the energy gap between the triplet state of
the ligand and the emissive level of the lanthanide ion should be greater than 2500 cm -1, while being less
than 3500 cm-1.13 This ensures that the energy gap is large enough to overcome back energy transfer while
being small enough to allow for efficient energy transfer to occur.

To estimate the singlet and triplet energy levels of the synthesized ligands, steady-state
fluorescence and time-resolved phosphorescence spectra were acquired of their corresponding Gd3+
complexes. Gd3+ is used in these measurements because its electronic levels are too high in energy to
participate in transfer from the quinoline antennae used in this study.44,45 Using the maximum wavelength
of the emission spectra for both fluorescence and phosphorescence measurements, the energy of the singlet
and triplet states for each compound could be ascertained. The calculated singlet and triplet state energies
for each complex can be seen in Table 2-6.

Table 2-6. Singlet and triplet state energies for each complex. Singlet energies were acquired through
fluorescence measurements at room temperature. Triplet energies were obtained through phosphorescence
emission spectra at 77 K. E refers to the energy difference between the triplet excited state of the ligand
and the excited state of the Eu3+ ion.
Compound

Singlet Energy (cm-1)

Gd-MP30
Gd-MP42
Gd-MP43
Gd-MP44
Gd-MP45
Gd-MP46
Gd-MP47
Gd-MP48

26300
26200
24200
26200
21900
19400
20000
21600

Triplet Energy
(cm-1)
19600
19800
19100
19100
18100
19100
19300
17600

E (cm-1)
2400
2600
1900
1900
900
1900
2100
400

Upon comparison of the triplet energies of each ligand to that of the 5D0 radiative excited state of
the Eu3+ ion, all complexes except Gd-MP42 were found to have energy gaps lower than the optimum 2500
cm-1 between the triplet excited state of the ligand and the 5D0 energy level of the Eu3+ ion.46–48 Gd-MP45
and Gd-MP48 exhibited the lowest triplet state energies of all of the compounds, with E values of 900 and
400 cm-1, respectively. This small energy gap enables back energy transfer from the lanthanide ion to the
ligand much more easily, 13 and provides the best explanation for the low emission intensities and quantum
yield values for the corresponding Eu3+ complexes. Gd-MP42 and Gd-MP30 have the highest energy gaps
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between the triplet state of the ligand and the radiative excited state of Eu3+, corresponding to their Eu3+
complexes displaying higher emission intensities. Although Eu-MP30 was shown to have the highest
quantum yield of all of the Eu3+ compounds, Eu-MP42 had only the 5th highest quantum yield value,
suggesting that other factors besides the triplet state energy levels could be playing a role in the measured
quantum yield of this complex. All other complexes displayed E values between 1900 – 2100 cm-1
consistent with their Eu3+ complexes having lower intensities and quantum yield values due to some amount
of back energy transfer.

Evaluation of Luminescence Lifetimes and Determination of q-values
Lanthanide ions such as Eu3+ exhibit long-lived luminescence lifetimes that make them ideal for
time-resolved detection. These long-lived luminescence lifetimes allow for the acquisition of signal after
background autofluorescence has subsided.49,50 Using luminescence lifetimes, the number of bound water
molecules can be calculated through comparison of the luminescence signal decay in both D 2O and H2O.
Water quenches luminescence intensity due to its O-H oscillating groups while the O-D oscillator in D2O
has negligible effects.7 This allows for the rates of decay in each solvent to be related to the number of
lanthanide-bound water molecules through the Horrocks equation (equation 4) where x is the number of
amide protons in each complex.24 The measured luminescence lifetime values for each compound and their
calculated q values can be found in Table 2-7.
𝑞 = 1.2[(𝑘𝐻2 𝑂 − 𝑘𝐷2 𝑂 ) − 0.25 − 0.075𝑥]

(4)

Table 2-7. Lifetime measurement and q values of 0.02 mM complexes in 0.1 mM HEPES buffer (pH 7.4)
and D2O.
Compound

 D2O (ms)

 H2O (ms)

k D2O (ms-1)

k H2O (ms-1)

q-value

Eu-MP30
Eu-MP42
Eu-MP43
Eu-MP44
Eu-MP45
Eu-MP46
Eu-MP47
Eu-MP48

1.93
0.893
0.358
0.532
0.152
0.623
0.682
0.611

0.504
0.417
0.213
0.293
0.133
0.301
0.325
0.292

0.519
1.12
2.79
1.88
6.57
1.61
1.47
1.64

1.98
2.40
4.69
3.42
7.55
3.32
3.08
3.42

0.916
0.602
1.35
0.915
0.239
1.12
1.00
1.21

As expected, the luminescence lifetime of each complex in water is shorter than that in D 2O. This
is due to the quenching effects of O-H oscillators of H2O that are not present in D2O. Aside from Eu-MP45,
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all compounds display luminescence lifetimes in D2O that are at least 2-fold greater than the lifetimes in
H2O. Eu-MP45 has lifetimes that are nearly identical in D2O and H2O. The calculated q values are indicative
of one bound water molecule on each complex except for Eu-MP45. These q values are consistent with
Eu(III) having nine coordination sites, eight of which are occupied by the donor atoms of the octadentate
ligands used in this study, and the ninth occupied by one bound water molecule.51 The method used to
estimate q values does exhibit an error of 0.5 and could be a possible explanation for the lower q value
measured for Eu-MP45.

Effect of pH on Luminescence Properties
Lanthanide complexes can be designed to be responsive to pH, a feature that could potentially be
used to detect pathological conditions that exhibit altered tissue pH.52 To evaluate the effect of pH on
emission and excitation properties, each compound was incubated at pH values ranging from 5.5 – 8.5.
Change in emission intensity of the hypersensitive band as a function of pH can be seen in Figure 2-9
respectively.
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Figure 2-9. Ratio of emission intensity at 614 nm and 592 nm versus pH. Samples were prepared at 0.1
mM in 0.1 M MES buffer (pH 5.5 and 6.5) and 0.1 M TRIS buffer (pH 7.5 and 8.5) with 0.1 M KCl.
Emission spectra were acquired at room temperature from 570-750 nm.
All complexes displayed an increase in the J = 2 (614 nm) to J = 1 (592 nm) emission intensity
ratio as pH was increased. Previous work by Woods and coworkers showed a similar trend which was
attributed to a combination of the deprotonation of the lanthanide-bound water molecule above pH 7, and
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deprotonation of the amide group brought about by an acceleration of proton exchange at higher pH. 53,54
The deprotonation of the amide would result in an increase in Eu3+ emission intensity due to a reduction in
the quenching effect of the closely oscillating amide protons.

Evaluation of Kinetic Stability
Evaluation of a compound’s kinetic stability is important to establish safety for use in vivo. Free
lanthanide ions pose a risk of heavy metal poisoning but when strongly chelated, pass through the body
intact.55 Previous studies showed that the stability of lanthanide complexes can be evaluated by monitoring
signal changes brought about by ligand exchange,56 transmetallation,57 or proton-assisted dissociation.58–60
To evaluate the kinetic stabilities of the library of compounds in this study, proton-assisted dissociation was
used wherein all compounds were incubated in acidic buffer, and their emission intensities monitored over
time. For complexes with low kinetic stabilities, their metal ions should be easily displaced by protons in
the buffer thus increasing their distance from the chromophore. The resultant effect would be a reduction
in emission intensity as the ability of the antenna to sensitize the emission intensity decreases. Plots of the
emission intensities of each compound at 21.4 oC and 37.8 oC are shown in Figure 2-10. Dissociation halflives were calculated by fitting the data to mono-exponential decay or linear functions (Table 2-8). Halflife values marked with an asterisk may not be indicative of the true value of stability due to the inability
to fit the data to a mono-exponential decay function.
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Figure 2-10. Plot of emission intensity at 615 nm over (A) 7 days at 21.4 oC and (B) 48 h at 37.8 oC.
Samples were prepared at 0.1 mM with 10 mM citrate buffer at pH 3. Emission measurements were
acquired from 570-750 nm with a slit width of 2 nm. Each data set was fit with a mono-exponential decay
fit (dashed line).
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Table 2-8. Calculated half-life values at 21.4 oC and 37.8 oC.
Compound
Eu-MP30
Eu-MP42
Eu-MP43
Eu-MP44
Eu-MP45
Eu-MP46
Eu-MP47
Eu-MP48

Half-life 21.4 C (h)
2.79
136
65600*
32.92
1240*
507*
308*
**

Half-life 37.8 C (h)
0.510
26.8
74.2*
4.08
118*
68.3*
66.4
99.3*

* Calculated using linear fit instead of mono-exponential decay fit.
** Unable to be calculated as the emission intensity did not decrease over
the testing period.

All compounds show greater half-life values at lower temperatures by at least 4-fold. This was to
be expected as increasing temperature usually causes an acceleration of reaction rates; in this particular
case, it results in a faster dissociation of the metal ion from the complex. 61 As shown in Figure 2-10, EuMP30 shows the poorest stability at both temperatures as its emission intensity decays completely after one
day at 21.4 oC and in less than 5 h at 37.8 oC. Eu-MP42 and Eu-MP44, also appear to dissociate quickly at
37.8 oC, with half-life values of 26.8 and 4.08 h, respectively. All other compounds exhibited higher
stability as their half-lives were greater than 60 h at higher temperatures. Eu-MP48 initially showed an
increase in emission intensity after 24 h at 21.4 oC, after which its emission intensity stayed relatively
constant for the remaining 6 days of data collection.

2.4 Conclusion
Lanthanide-based complexes have the potential to act as bimodal agents for MRI and optical
imaging. The long-lived luminescence lifetimes of Eu3+ can be utilized to overcome the limitations of
traditional optical imaging probes such as autofluorescence. This study evaluated the effect of the amide
position of quinoline antennae on the luminescence properties of a series of Eu3+ complexes. It was found
that the amide substituent on the aminoquinoline antenna does affect the luminescent properties as well as
the stability of each of the compounds. This is possibly due to changes in the pi-system of each antenna
brought about by the location of the amide substituent relative to the nitrogen in the ring. While Eu-MP30
was found to have the highest emission intensity and quantum yield value of all the complexes, this
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compound’s emission signal decayed at the fastest rate under acidic conditions, thus indicating poor kinetic
stability. The direct coordination of the quinoline antenna to the Eu3+ metal center showed the highest
sensitization of the lanthanide’s luminescence due to the shorter distance between the antenna and the
lanthanide ion. In contrast, Eu-MP48 and Eu-MP45 had emission signal that remained stable under acidic
conditions, indicating good kinetic inertness, but displayed the lowest emission intensity and quantum yield
values of all the complexes. The position of the nitrogen on the aminoquinoline antenna for Eu-MP45 and
Eu-MP48 resulted in a smaller energy gap between the triplet energy level of the ligand and the emissive
level of the lanthanide ion. The smaller energy gap may have resulted in substantial back energy transfer
that led to the low emission intensity of these two complexes. For in vivo applications, the ideal optical
imaging agent should possess high quantum yield and high stability. Of all the complexes in this study, EuMP43, Eu-MP46, and Eu-MP47 exhibit a reasonable balance of these two features, with quantum yields
between 0.0043 – 0.0105 and dissociation half-lives above 48 h at 37.8 oC. These features make these
complexes the most promising for future studies. Additionally, all complexes were found to have one
bound water molecule, which is a necessary feature for the generation of MRI contrast through water proton
exchange. Future work will include performing energy calculations to better understand the correlation
between amide position on the aminoquinoline antenna and luminescence properties, and evaluation of the
MRI properties of the library of complexes to determine the ability of these compounds to act as bimodal
imaging agents.
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Chapter 3. Effects of Antenna and Side-Chain Identities on the Optical and
PARACEST MRI Properties of Tb(III) and Eu(III) Complexes
Abstract
The MR and optical properties of Ln(III) complexes are significantly influenced by several factors
that include ligand structure, metal ion identity, and the number of bound water molecules. Systematic
variation and investigation of these factors in a complex allows for a better understanding of their effects
on its MR and optical features. The goal of this study was to evaluate the effect of varying ligand sidechains on the MRI and optical properties of europium and terbium complexes. To this end, three pyridineand quinoline- containing ligands were synthesized and characterized. Their respective Tb(III) and Eu(III)
complexes were prepared, and the luminescence and PARACEST MRI properties evaluated. Results
showed that emission intensities and quantum yield values varied with ligand side-chain and metal ion
identities while the excitation and absorption properties remained largely unaffected. All complexes were
estimated to have one coordinated water molecule, the presence of which allowed the observation of a
PARACEST effect for the Eu(III) complexes. Preliminary CEST studies of the pyridine-containing Eu(III)
complexes showed a variation in CEST signal with different side-chains. The metal complexes with more
amide protons exhibited the broadest CEST peaks and largest CEST signals while complexes with
carboxylate groups showed sharp and less intense CEST peaks. The CEST signal of the aspartate-containing
complex was also found to increase at higher temperatures, which may indicate more optimal exchange
kinetics at physiological temperatures.
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3.1 Introduction
PARACEST Agents
Paramagnetic Chemical Exchange Saturation Transfer (PARACEST) agents represent an
alternative class of MRI contrast agents that utilize the chemical exchange of labile and bulk water protons
to generate contrast.1 Typical agents are lanthanide ions, other than Gd3+, chelated with an octadentate
ligand such as 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraamide (DOTA-tetraamide).2 The fast water
water exchange kinetics, and excellent T1-shortening properties of Gd3+ agents are highly detrimental for
PARACEST MRI.2 An example PARACEST agent with a DOTA tetraamide ligand can be seen in Figure
3-1.

Figure 3-1. An example PARACEST agent with a DOTA tetraamide ligand. The Ln3+ is any lanthanide
ion besides Gd3+.

PARACEST agents have some notable advantages over typical Gd(III) based contrast agents. One
such advantage is that they can be turned “on” and “off” with the application of a selective radiofrequency
pulse, which could potentially shorten the time needed to acquire a complete MRI scan. 3 PARACEST
agents can also be designed to be responsive to changes in chemical environments such as pH and oxidative
stress.4 Acidic pH is a common biomarker used to characterize tumor microenvironments.5 Needle biopsy
can typically be used to measure the pH of surface accessible tumors, but MRI would be a noninvasive
approach that could be used to assess tumors at any location in the body.6 Changes in redox environments
can also be indicative of pathophysiological conditions such as ischemia.7 The ability to use MRI to better
detect minute changes in redox environment could help in better diagnosis of potentially fatal conditions.

An additional advantage of PARACEST agents is that their MRI signal has the potential to be
concentration independent by applying ratiometric methods, which involve using a non-responsive
reference complex.8 Ratiometric methods are used to determine physiological characteristics such as pH by
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monitoring the CEST properties of two magnetically different CEST sites.9,10 One site shows dependency
on the variable of interest while the other site is not affected.11 The ratio of the bulk water signal from the
two pools provides information of the variable of interest without necessitating knowledge of the exact
concentration of contrast agent.11 While in vitro studies of PARACEST agents have shown potential for
improved medical diagnosis, their translation in vivo has been limited due to signal losses caused by a
phenomenon called T2 exchange.

The T2 Exchange Mechanism
The T2 exchange (T2ex) effect is a relaxation process that causes a local decrease in the bulk water
signal similar to the contrast provided by PARACEST agents.12 This effect has been found to occur through
the same slow-to-intermediate exchange of labile protons and/or inner-sphere water molecules with bulk
water that is characteristic of PARACEST agents.12

Figure 3-2. MR images of healthy mouse kidneys displaying T2ex contrast due to a 0.5 mmol/kg
intravenous dose of a PARACEST agent at 37 oC (a-c) and 25oC (d-f); (a,d) kidneys pre injection; (b,e)
kidneys post injection, (c,f) pre minus post.13

The T2ex process causes a severe darkening of an MR image upon injection of a PARACEST agent
(Figure 3-2). This darkening occurs post injection without the need to “turn on” the PARACEST agent with
a selective radiofrequency pulse; and is more pronounced at physiological temperatures.12,13 Although this
competing T2ex mechanism has been viewed as a new source of MRI contrast, discrimination between MR
image darkening caused by T2ex and that caused by the CEST effect presents a significant problem that
needs to be addressed in order to be able to apply responsive PARACEST agents in vivo.12–14
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Several researchers have attempted to overcome the loss of signal intensity caused by the T 2ex
mechanism. These studies focused on utilizing optimum exchange rates and imaging sequence parameters.
Soesbe et al. showed that the PARACEST and T2ex contrast mechanisms reach maximum signal intensities
at different exchange rates and have suggested selecting an exchange rate that maximizes the PARACEST
signal while minimizing the T2ex signal.13 This group also suggested using imaging agents with slow-tointermediate water exchange at lower magnetic fields where T 2ex is less prominent.13 The lower magnetic
field, combined with a novel pulse imaging sequence utilizing short echo times (TE) and sweep imaging
with Fourier transform (SWIFT) pulse sequencing, enabled PARACEST MR imaging with little
interference from T2ex.13 The use of short TEs allowed the detection of short T2 components as normal echo
times were not short enough to capture MR signal from regions of reduced T 2 caused by PARACEST
agents.13 This study highlighted the promise of using PARACEST agents in vivo upon elimination of the
T2ex effect.

In another study, Soesbe and coworkers investigated the T2ex properties of three Eu3+ complexes,
EuTETA-, EuDOTA-(gly)4-, and EuDOTA-, that exhibit very slow, slow-to-intermediate, and fast water
exchange, respectively.12 EuTETA- (very slow exchange) and EuDOTA- (fast exchange) only displayed
slight darkening of the renal pelvis during renal clearance 30 minutes post injection, while EuDOTA-(gly)4(slow-to-intermediate exchange) showed dramatic darkening of the kidneys and surrounding tissue post
injection (Figure 3-3).12 These results suggest that designing PARACEST agents that exhibit fast water
exchange may serve as a viable way to eliminate loss of signal due to T2ex.

Figure 3-3. MR images of healthy mouse kidneys before and after 0.25 mmol/kg intravenous injection of
(a) EuDOTA-, (b) EuDOTA-(gly)4-, and (c) EuTETA-. Post injection images of those agents with no
exchange and fast exchange (a, c) show little darkening of the renal veins while the agent with slow-tointermediate water exchange shows severe darkening of the entire image.12
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Lanthanide Coordination Geometries
As previously mentioned, typical PARACEST agents comprise a lanthanide ion chelated with a
ligand such as DOTA-tetraamide, which is known to form thermodynamically stable and kinetically inert
complexes with lanthanide ions.1,2,15,16 This can be attributed to a properly sized cavity in the ligand to
adequately fit lanthanide ions.17 DOTA-tetraamide ligands are also octadentate, allowing the lanthanide ion
to bind to 8 sites on the ligand with one site available to bind one water molecule.18

In solution, DOTA-based Ln(III) complexes form two isomers that adopt the monocapped square
antiprism (SAP) and monocapped twisted square antiprism (TSAP) geometries. 19 These isomers can
interconvert through pendant arm rotation or ring flipping to form two diastereomers that form
enantiometric pairs (Figure 3-4).19 The enantiometric pairs are denoted as (), () and (),
() where  and  refer to an arm rotation clockwise and counterclockwise, respectively, while 
and  refer to clockwise and counterclockwise ring helicities, respectively. The latter pair of
enantiomers have TSAP geometry while the former pair have SAP geometry. 18

Figure 3-4. Isomer geometries of typical DOTA complexes. Interconversion between SAP and TSAP
isomers occurs through arm rotation or ring inversion to form two diastereomers.20
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The differences in conformation due to each isomer geometry results in distinct properties for the
lanthanide complex. TSAP isomers have a more open structure due to the twisting about their metal center
while SAP isomers have a more compact, rigid structure.21 Due to its expanded structure, TSAP isomers
exhibit longer coordination bonds between the Ln3+ ion and the bound water.21 This allows for water
exchange rates that are up to 50 times faster than that of SAP isomers.20,22,23 For typical PARACEST
applications that rely on the generation of contrast through slow-to-intermediate exchange of bound water
molecules, SAP isomers are preferred because the water exchange of TSAP isomers is too fast to observe
the CEST effect.24 However, CEST can also occur between bulk water protons and -NH or -OH protons
bound to the PARACEST agent, and the CEST signal that arises from the amide or hydroxyl protons can
be detected for both the SAP and TSAP isomers.25 In this case, complexes with rapidly exchanging bound
water molecules are preferred so that there is no loss of signal due to T2ex.3 Hence, the design of
PARACEST agents that preferentially adopt the TSAP geometry in solution and can produce a CEST signal
through exchange of amide or hydroxyl protons could result in complexes that exhibit fast enough bound
water exchange kinetics to overcome the aforementioned T2ex mechanism.

The incorporation of lanthanide ions such as Tm3+ in complexes that primarily adopt the TSAP
geometry in solution results in narrower line widths in PARACEST spectra, which corresponds to increased
sensitivity.26 As seen in Figure 3-5, a CEST signal from the TSAP isomer of a Tm3+ DOTA-tetraamide
complex is much greater than that of the SAP isomer and has a larger chemical shift. Fast water exchange
kinetics associated with the TSAP isomer can often cause a broadening of signal, but use of lanthanide ions
such as Tm3+ have the potential to combat this issue and provide more useable signal.27

Figure 3-5. Plots showing the CEST chemical shifts of amide pools of Tm3+ DOTAM complexes of both
TSAP and SAP species with varying temperature from 308 to 315 K.26
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Previous studies have established that the SAP/TSAP isomer ratio for a given Ln(III) complex can
change depending on ligand environment.28 Specifically, increasing the steric strain at the site of water
coordination has been found to favor adoption of the TSAP geometry in solution, while complexes with
less bulky substituents tend to favor the SAP geometry.23,28 The increased steric hindrance of the water
coordination site results in faster bound water-exchange rates due to crowding of the water-coordination
site, which favors the dissociation of the coordinated water molecule.28

The steric hindrance of a metal complex can be increased in multiple ways. In one study, increasing
the size of ligand side-chains by one carbon resulted in water exchange rates up to 15 times faster than the
shorter ligand.29 This same study found that increasing the size of the macrocyclic ring from a 5-membered
chelate in a DOTA-monoamide ligand to a 7-membered chelate resulted in an acceleration of exchange
rates by a factor of 69.29 Merbach and coworkers showed that elongating the macrocyclic backbone through
the addition of an extra carbon was another way to increase the water exchange rate.30 This resulted in a
water exchange rate that was 100-fold faster.30 The use of bulky phosphonate arms resulted in faster water
exchange as well due to increased steric hindrance of the molecule.31,32 Lastly, multiple groups showed that
the ratio of TSAP/SAP geometries increased with an increasing number of alkyl groups between the amide
group and carboxyl group of the attached sidearm of the ligand.33,34 The general consensus of the mentioned
studies is that an increase in the steric hindrance of a compound results in an increase in the predominance
of the TSAP isomer in solution.23,35,36

Project Goal
The main goal of this project was to develop a library of dual-modality Ln3+ complexes with
directly coordinated pyridine and quinoline moieties. Pyridine groups have been known to sensitize the
luminescence of Tb3+ while quinoline groups sensitize the luminescence of Eu3+ through the antenna
effect.37,38 In this project, we sought to investigate the influence of other non-antenna side-chains on the
optical and PARACEST MRI properties of the library of complexes. The central hypothesis of this study
is that the presence of the bulky pyridine and quinoline sidearms would cause a favored adoption of the
TSAP geometry in solution, and this could potentially result in faster bound water exchange kinetics and a
reduction of the T2ex effect. These selected antennae were also expected to allow for the sensitization of the
lanthanide centers for optical imaging. The complexes used in this study can be found in Chart 3-1.
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Chart 3-1. Final synthesized complexes used in this study. Lanthanides used are Tb3+, Eu3+ and Tm3+.
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3.2 Experimental Methods
Materials and Instrumentation
All reagents and solvents were purchased from commercial sources and used as received. DI water
was used in all reactions. Flash Chromatography was carried out using a Buchi Reveleris X2 system. 1H
and 13C NMR spectra were recorded on a Varian 500 MHz NMR spectrometer. Inductively Coupled Plasma
was performed using a Perkin Elmer 5300 DV optical emission ICP. High performance liquid
chromatography (HPLC) was performed using an Agilent 1100 Series HPLC. UV-Vis absorption spectra
were acquired using a Cary 5000 UV-Vis-NIR spectrophotometer. Luminescence studies were performed
using a Jobin-Yvon Horiba Fluoromax spectrometer.

Synthesis and Purification

Scheme 3-1. Synthesis of Ln-MP9b
1-(2-Pyridinylmethyl)-1,4,7,10-tetraazacyclododecane (MP1). Cyclen (1.999 g, 11.60 mmol)
and picolyl chloride hydrochloride (0.474 g, 2.89 mmol) were dissolved in CHCl3 (50 mL). K2CO3 (0.478
g, 3.19 mmol) was added and the reaction mixture was stirred to reflux overnight. The reaction mixture was
washed with water (1 x 40 mL) and extracted with HCl (0.3 M, 3 × 25 mL). The aqueous layer was
recovered, and the pH adjusted to pH 8. The layer was then extracted with CHCl3 (3 × 25 mL). The pH of
the aqueous layer was further adjusted to pH 11 and extracted with CHCl3 (6 × 25 mL). The solution was
dried with Na2SO4, filtered, and the solvent removed under reduced pressure to give a yellow oil (0.712 g,
91%). 1H NMR (CDCl3,500 MHz):  2.54-2.57 (m, 4H, NCH2CH2N), 2.61-2.67 (m, 8H, NCH2CH2N),
2.78-2.80 (m, 4H, NCH2CH2N), 3.75 (s, 2H, NCH2-py), 7.13 (m, 1H, py-H5), 7.41-7.43 (d, 1H, J = 10
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MHz, py-H3), 7.63-7.65 (td, 1H, J = 5 MHz, py-H4), 8.47-8.48 (d, 1H, J = 5 MHz, py-H6). 13C NMR
(CDCl3,125 MHz):  44.97 46.01, 51.56, 61.01, 122.11, 123.02, 136.66, 148.88, 159.48.
2‐[4,7‐bis(carbamoylmethyl)‐10‐[(pyridin‐2‐yl)methyl]‐1,4,7,10‐tetraazacyclododecan‐1yl]acetamide (MP9b). To a solution of 1-(2-Pyridinylmethyl)-1,4,7,10-tetraazacyclododecane (0.362 g,
1.37 mmol) in acetonitrile (10 mL) and triethylamine (0.766 mL, 5.50 mmol), 2-bromoacetamide (0.587 g,
4.26 mmol) was added. The mixture was stirred to reflux overnight, and the formation of a white precipitate
was observed. The precipitate was isolated by vacuum filtration, washed with cold acetonitrile, and left to
air dry to yield the final product as a white solid (0.328 g, 55%). 1H NMR (D2O, 500 MHz): δ 2.47-2.55
(m, 16H, NCH2CH2N), 2.9-2.97 (m, 6H, NCH2C=O), 3.53 (s, 2H, NCH2-py), 7.2 (t, 1H, J = 10 MHz, pyH5), 7.29 (d, 1H, J = 5 MHz, py-H3), 7.67 (td, 1H, J = 10 MHz, py-H4), 8.29 (d, 1H, J = 5 MHz, py-H6).
13C

NMR (D2O, 125 MHz): δ 51.67, 52.36, 57.10, 60.41, 123.12, 124.78, 137.78, 148.14, 177.65. LRMS

(ESI-MS): m/z calcd. for C20H36N8O32+, [M+2H]2+, 218.1, found 218.3; calcd. for C20H35N8O3+, [M+H]+,
435.3, found 435.4; calcd. for C20H34N8NaO3+ [M+Na]+ , 457.3, found 457.4.

Scheme 3-2. Synthesis of Ln-MP13
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Tert‐butyl

2‐{2‐[4,7‐bis({[2‐(tert‐butoxy)‐2‐oxoethyl]carbamoyl}methyl)‐10‐[(pyridin‐2‐

yl)methyl]‐1,4,7,10‐tetraazacyclododecan‐1‐yl]acetamido}acetate (MP8). To a solution of MP1 (0.362
g, 1.37 mmol) in acetonitrile (25 mL), glycine, N-(2-bromoacetyl)-, 1,1-dimethylethyl ester (1.076 g, 4.26
mmol) and potassium carbonate (0.7598 g, 5.50 mmol) were added. The mixture was stirred to reflux
overnight. Potassium carbonate was filtered with a fritted funnel. The solvent was removed under reduced
pressure, and the crude product was dissolved in dichloromethane (5 mL) and purified by flash
chromatography (DCM/EtOH 95/5 v/v, Rf = 0.05) to yield an amber solid (0.651 g, 60.96%). 1H NMR
(CDCl3, 500 MHz): δ 1.36-1.43 (m, 27H, OC(CH3)3), 2.34-2.98 (m, 16H, NCH2CH2N), 3.17-3.38 (m, 6H,
NCH2C=O), 3.54 (s, 2H, NCH2-py), 3.80-3.90 (m, 6H, NHCH2COO), 7.13 (d, 1H, J = 5 MHz, py-H5),
7.59 (td, 1H, J = 5 MHz, py-H3), 7.94 (t, 1H, J = 10 MHz, py-H4), 8.37 (d, 1H, J = 5 MHz, py-H6). 13C
NMR (CDCl3, 125 MHz): δ 28.02, 41.71, 50.42, 57.38, 59.46, 81.54, 123.39, 123.50, 136.81, 150.12,
158.03, 168.60, 168.86, 171.71, 172.13.
2‐[2‐(4,7‐di{[(carboxylatomethyl)carbamoyl]methyl}‐10‐[(pyridin‐2‐yl)methyl]‐1,4,7,10‐
tetraazacyclododecan‐1‐yl)acetamido]acetate (MP13). MP8 (0.5174 g, 0.665 mmol) was dissolved in
dichloromethane (4 mL) and added dropwise to a cooled trifluoroacetic acid (6 mL). The solution was
stirred at room temperature for 48 h. The solvent was removed under reduced pressure, and the product was
dissolved in H2O (10 mL). The pH was adjusted to 6 and lyophilized for 72 h to yield a yellow solid (1.332
g, quantitative). 1H NMR (D2O, 500 MHz): δ 2.98-3.09 (m, 16H, NCH2CH2N), 3.26-3.34 (m, 6H,
NCH2C=O), 3.54-3.71 (m, 6H, O=CNHCH2), 4.38 (s br, 2H, NCH2-py), 7.38 (t, 1H, J = 5 MHz, py-H5),
7.46 (d, 1H, J = 10 MHz, py-H3), 7.80 (t, 1H, J = 5 MHz, py-H4), 8.44 (d, 1H, J = 5 MHz, py-H6). 13C
NMR (D2O, 125 MHz): δ 43.00, 48.87, 55.23, 57.90, 124.76, 128.75, 138.66, 149.66, 162.82, 176.23,
176.26. LRMS (ESI-MS): m/z calcd. for C26H42N8O92+, [M+2H]2+, 305.2, found 305.4; calcd. for
C26H41N8O9+, [M+H]+, 609.3, found 609.4; calcd. for C26H40N8NaO9+ [M+Na]+ , 631.3, found 631.3.
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Scheme 3-3. Synthesis of Ln-MP28
1,4‐di‐tert‐butyl 2‐{2‐[4,7‐bis({[1,4‐bis(tert‐butoxy)‐1,4‐dioxobutan‐2‐yl]carbamoyl}methyl)‐
10‐(pyridin‐2‐ylmethyl)‐1,4,7,10‐tetraazacyclododecan‐1‐yl]acetamido}butanedioate (MP19). To a
solution of MP1 (0.381 g, 1.45 mmol) in acetonitrile (20 mL), 1,4‐di‐tert‐butyl 2‐(2chloroacetamido)butanedioate (1.441 g, 4.48 mmol) and potassium carbonate (0.801 g, 5.79 mmol) were
added. The mixture was stirred to reflux overnight. The solvent was removed under reduced pressure, and
the crude product was dissolved in dichloromethane (5 mL) and purified by flash chromatography
(DCM/EtOH 95/5 v/v, Rf = 0.20). Compound MP19 was obtained as a yellow solid (0.917 g, 56.6%). 1H
NMR (CDCl3, 500 MHz): δ 1.33-1.44 (m, 54H, OC(CH3)3), 2.79-2.92 (m, 16H, NCH2CH2N), 3.08-3.55
(m, 15H, NCH2CNHCHCH2) 4.65-4.68 (m, 2H, NCH2-py), 7.11 (d, 1H, J = 5 MHz, py-H5), 7.55 (m, 1H,
py-H3), 7.72 (t, 1H, J = 5 MHz, py-H4), 8.58 (s, 1H, py-H6). 13C NMR (CDCl3, 125 MHz): δ 18.43, 27.89,
28.05, 37.20, 52.93, 53.42, 58.38, 81.12, 82.00, 169.59, 169.68, 170.09, 170.19.
2‐{2‐[4‐({[3‐(tert‐butoxy)‐1‐carboxy‐3‐oxopropyl]carbamoyl}methyl)‐10‐{[(1,2‐
dicarboxyethyl)carbamoyl]methyl}‐7‐(pyridin‐2‐ylmethyl)‐1,4,7,10‐tetraazacyclododecan‐1‐
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yl]acetamido}butanedioic acid (MP28). MP19 (0.8429 g, 0.753 mmol) was dissolved in dichloromethane
(4 mL) and added dropwise to cooled trifluoroacetic acid (6 mL). The solution was stirred at room
temperature for 48 h. The solvent was removed under reduced pressure, and the crude product was
redissolved in dichloromethane (5 mL). The solvent was removed again under reduced pressure and the
product was dissolved in H2O (10 mL). The pH was adjusted to 6 and lyophilized for 72 h to yield a white
solid (1.839 g, quantitative). 1H NMR (D2O, 500 MHz): δ 2.34-2.66 (m, 8H, NCH2CH2N), 3.07-3.13 (m,
8H, NCH2CH2), 3.19 (s br, 2 H, NCH2C=O), 3.28 (s br, 6H, NHCHCH2), 3.34 (s br, 4H, NCH2C=O), 3.98
(s, 1H, NHCHCH2), 4.26-4.27 (m, 2H, NHCHCH2), 4.47 (s, 2H, NCH2-py), 7.39 (t, 1H, J = 5 MHz, pyH5), 7.44 (d, 1H, J = 5 MHz, py-H3), 7.81 (t, 1H, J = 10 MHz, py-H4), 8.57 (d, 1H, J = 5 MHz, py-H6).
13C

NMR (D2O, 125 MHz): δ 39.41, 48.41, 50.81, 51.39, 52.99, 53.17, 53.58, 54.24, 54.96, 57.59, 124.52,

124.78, 138.71, 149.71, 170.41, 178.38, 178.61, 178.66. LRMS (ESI-MS): m/z calcd. for C32H48N8O152+,
[M+2H]2+, 392.2, found 392.4; calcd. for C32H47N8O15+, [M+H]+, 783.3, found 783.2; calcd. for
C32H46N8NaO15+ [M+Na]+ , 805.3, found 805.3.

Scheme 3-4. Synthesis of Ln-MP30
2‐[(1,4,7,10‐tetraazacyclododecan‐1‐yl)methyl]quinoline (MP27): Cyclen (2.000 g, 11.61
mmol) and 2-(chloromethyl)quinoline hydrochloride (0.622 g, 2.9 mmol) were dissolved in CHCl3 (50 mL).
K2CO3 (0.883 g, 6.38 mmol) was added after which the reaction mixture was stirred to reflux overnight.
The reaction mixture was washed with water (1 x 40 mL) and extracted with HCl (0.3 M, 3 × 25 mL). The
aqueous layer was recovered, and the pH adjusted to 8. The layer was then extracted with CHCl 3 (3 × 25
mL). The pH was further adjusted to pH 11 and extracted with CHCl3 (6 × 25 mL). The solution was dried

83

with Na2SO4, filtered, and the solvent removed under reduced pressure to give a yellow/brown oil (0.892
g, 96%). 1H NMR (CDCl3, 500 MHz): δ 2.57-2.59 (t, 4H, J = 5 MHz, NCH2CH2N), 2.68-2.69 (d, 8H, J =
5 MHz, NCH2CH2N), 2.81-2.83 (t, 4H, J = 5 MHz, NCH2CH2N), 3.92 (s, 2H, NCH2-quin), 7.45-7.49 (td,
1H, J = 5 MHz, quin-H3), 7.58-7.60 (d, 1H, J = 10 MHz, quin-H6), 7.63-7.67 (td, 1H, J = 10 MHz, quinH7), 7.74-7.76. (d, 1H, J = 10 MHz, quin-H8), 8.00-8.02 (d, 1H, J = 5 MHz, quin-H5), 8.11-8.13 (d, 1H, J
= 10 MHz, quin-H4). 13C NMR (CDCl3, 125 MHz): δ 45.13, 46.14, 46.32, 47.11, 51.91, 62.01, 120.87,
126.06, 127.46, 127.58, 128.88, 129.32, 136.67, 147.51, 160.27
2‐[4,7‐bis(carbamoylmethyl)‐10‐[(quinolin‐2‐yl)methyl]‐1,4,7,10‐tetraazacyclododecan‐1‐
yl]acetamide (MP30): To a solution of MP27 (0.390 g, 1.24 mmol) in acetonitrile (20 mL) and
triethylamine (0.6937 mL, 4.98 mmol), 2-bromoacetamide (0.532 g, 3.86 mmol) was added. The mixture
was stirred to reflux overnight. A white solid formed and the reaction mixture was vacuum filtered. The
resulting white solid (0.354 g, 59%) was left to air dry. 1H NMR (D2O, 500 MHz): δ 2.28-2.43 (m, 16H,
NCH2CH2N), 2.71 (s, 4H, NCH2C=O), 2.87-2.91 (m, 2H, NCH2C=O), 3.34 (s, 2H, NCH2-quin), 7.12-7.14
(d, 1H, J = 10 MHz, quin-H3), 7.35-7.38 (m, 1H, quin-H6), 7.33-7.56 (m, 1H, quin-H7), 7.64-7.66 (d, 1H,
J = 10 MHz, quin-H8), 7.73-7.75 (d, 1H, J = 10 MHz, quin-H5), 7.96-7.98 (d, 1H, J = 10 MHz, quin-H4).
13C

NMR (D2O, 125 MHz): δ. 51.90, 52.27, 52.50, 56.97, 57.02, 57.15, 61.09, 121.67, 126.85, 126.99,

127.11, 127.98, 130.35, 137.64, 146.11, 158.66, 177.12, 177.29. LRMS (ESI-MS): m/z calcd. for
C25H37N8O3+ [M+H]+, 485.3, found 485.4; calcd. for C25H38N8O32+ [M+2H]2+, 243.2, found 243.3; calcd.
for C25H36N8NaO3+ [M+Na]+, 507.3, found 507.3.
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Scheme 3-5. Synthesis of Ln-MP33
Tert‐butyl 2‐{2‐[4,7‐bis({[2‐(tert‐butoxy)‐2‐oxoethyl]carbamoyl}methyl)‐10‐[(isoquinolin‐3‐
yl)methyl]‐1,4,7,10‐tetraazacyclododecan‐1‐yl]acetamido}acetate (MP31): To a solution of M27
(0.416 g, 1.33 mmol) in acetonitrile (20 mL), glycine, N-(2-bromoacetyl)-, 1,1-dimethylethyl ester (0.856
g, 4.11 mmol) and potassium carbonate (0.735 g, 5.31 mmol) were added. The mixture was stirred to reflux
overnight. The solvent was removed under reduced pressure, and the crude product was dissolved in
dichloromethane (5 mL) and purified by flash chromatography (DCM/EtOH 93/7 v/v, R f = 0.106).
Compound MP31 was obtained as a golden brown solid (0.488 g, 44.5%). 1H NMR (CDCl3, 500 MHz): δ
1.19-1.44 (m, 27H, OC(CH3)3), 2.72-3.19 (m, 22H, NCH2CH2NHCH2C=O), 3.82-3.92 (m, 8H, NHCH2quin), 7.39-7.41 (d, 1H, J = 10 MHz, quin-H3), 7.50-7.53 (m, 1H, quin-H6), 7.68-7.71 (m, 1H, quin-H7),
7.77-7.79 (d, 1H, J = 10 MHz, quin-H8), 7.83 (s br, 1H, NCH2C=ONH), 7.99-8.01 (d, 1H, J = 10 MHz,
quin-H5), 8.07-8.09 (d, 1H, J = 10 MHz, quin-H4), 8.35 (s br, 2H, NCH2C=ONH). 13C NMR (CDCl3, 125
MHz): δ 25.32, 41.48, 52.61, 52.81, 53.10, 53.23, 58.27, 59.39, 59.69, 62.10, 64.30, 81.58, 81.81, 121.66,
126.45, 127.16, 127.63, 128.54, 129.87, 136.62, 147.61, 159.19, 168.96, 169.08, 171.50, 171.71
2‐[2‐(4,7‐di{[(carboxymethyl)carbamoyl]methyl}‐10‐[(isoquinolin‐3‐yl)methyl]‐1,4,7,10‐
tetraazacyclododecan‐1‐yl)acetamido]acetic acid (MP33): MP31 (0.488 g, 0.590 mmol) was dissolved
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in dichloromethane (4 mL) and added dropwise to a cooled trifluoroacetic acid (6 mL). The solution was
stirred at room temperature for 48 h. The solvent was removed under reduced pressure, and the crude
product was washed with dichloromethane (2 × 5 mL). The solvent was removed again under reduced
pressure and the product was dissolved in H2O (10 mL). The pH was adjusted to 6 and lyophilized for 72 h
to yield a golden brown solid (1.464 g, quantitative). 1H NMR (D2O, 500 MHz): δ 3.01-3.26 (m br, 16H,
NCH2CH2N), 3.43-3.75 (m br, 12H, CH2CNHCH2), 4.46 (s, 2H, NCH2-quin), 7.51-7.53 (d, 1H, J = 10
MHz, quin-H3), 7.56-7.59 (m, 1H, quin-H6), 7.73-7.76 (m, 1H, quin-H7), 7.89-7.90 (d, 1H, J = 5 MHz,
quin-H8), 8.00-8.02 (d, 1H, J = 10 MHz, quin-H5), 8.30-8.31 (d, 1H, J = 5 MHz, quin-H4). 13C NMR
(D2O, 125 MHz): δ 30.18, 42.75, 43.23, 51.35, 51.42, 54.87, 58.63, 58.65, 112.80, 115.12, 117.45, 119.77,
127.80, 128.14, 130.95, 139.02, 146.28, 162.53, 162.81, 163.09, 163.38, 176.04, 176.26. LRMS (ESIMS): m/z calcd. for C30H44N8O92+, [M+2H]2+, 330.2, found 330.4.

Scheme 3-6. Synthesis of Ln-MP34
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1,4‐di‐tert‐butyl

2‐{2‐[4,7‐bis({[1,4‐bis(tert‐butoxy)‐1,4‐dioxobutan‐2‐yl]carbamoyl}methyl)‐10‐

[(isoquinolin‐3‐yl)methyl]‐1,4,7,10‐tetraazacyclododecan‐1‐yl]acetamido}butanedioate (MP32): To a
solution of MP27 (0.492 g, 1.57 mmol) in acetonitrile (20 mL), 1,4‐di‐tert‐butyl 2‐(2chloroacetamido)butanedioate (1.566 g, 4.87 mmol) and potassium carbonate (0.870 g, 6.28 mmol) were
added. The mixture was stirred to reflux overnight. The solvent was removed under reduced pressure, and
the crude product was dissolved in dichloromethane (5 mL) and purified by flash chromatography
(DCM/EtOH 95/5 v/v, Rf = 0.209). Compound MP32 was obtained as a golden brown solid (2.309 g,
56.6%). 1H NMR (CDCl3, 500 MHz): δ 1.37-1.46 (m, 54H, OC(CH3)3), 2.48-2.82 (m, 28H, NCH2CH2N),
2.89-3.24 (m, 12H, CH2CNHCHCH2) 3.97-4.12 (m, 2H, NCH2-quin), 4.65 (s br, 3H, NHCHCH2), 7.477.51 (m, 1H, quin-H3), 7.66-7.69 (m, 1H, quin-H6), 7.74-7.78 (m, 1H, quin-H7), 7.83-7.84 (d br, 1H, J =
5 MHz, quin-H8), 7.98-8.03 (m, 1H, quin-H5), 8.23-8.27 (m, 1H, quin-H4). 13C NMR (CDCl3, 125 MHz):
δ 18.42, 27.79, 27.88, 27.90, 27.93, 27.96, 28.00, 28.02, 28.06, 28.08, 28.09, 28.11, 37.28, 37.44, 42.44,
48.84, 49.33, 52.14, 52.75, 52.88, 53.31, 54.20, 58.36, 59.44, 81.14, 81.90, 81.98, 121.67, 127.42, 127.65,
128.99, 136.82, 147.56, 169.59, 169.69, 169.75, 170.11, 170.19, 171.02
2‐{2‐[4,7‐bis({[(1,2‐dicarboxyethyl)carbamoyl]methyl})‐10‐[(isoquinolin‐3‐yl)methyl]‐
1,4,7,10‐tetraazacyclododecan‐1‐yl]acetamido}butanedioic acid (MP34): MP32 (1.042 g, 0.891 mmol)
was dissolved in dichloromethane (4 mL) and added dropwise to a cooled trifluoroacetic acid (6 mL). The
solution was stirred at room temperature for 48 h. The solvent was removed under reduced pressure, and
the crude product was washed with dichloromethane (2 × 5 mL). The solvent was removed again under
reduced pressure and the product was dissolved in H2O (10 mL). The pH was adjusted to 6 and lyophilized
for 72 h to yield a white solid (2.309 g, quantitative). 1H NMR (D2O, 500 MHz): δ 2.21-2.70 (m, 8H,
NCH2CH2N), 3.15-3.18 (m, 8H, NCH2CH2N), 3.36-3.67 (m, 12H, CH2CNHCHCH2), 4.04 (s, 1H,
NHCHCH2), 4.17-4.20 (dd, 2H, J = 5 MHz, NCH2-quin), 4.33-4.36 (dd, 1H, J = 5 MHz, NHCHCH2), 4.464.48 (dd, 1H, J = 10 MHz, NHCHCH2), 7.48-7.50 (d, 1H, J = 10 MHz, quin-H3), 7.57-7.60 (m, 1H, quinH6), 7.78-7.81 (m, 1H, quin-H7), 7.89-7.91 (d, 1H, J = 10 MHz, quin-H8), 8.18-8.19 (d, 1H, J = 5 MHz,
quin-H5), 8.33-8.35 (d, 1H, J = 10 MHz, quin-H4). 13C NMR (CDCl3, 1265MHz): δ 39.29, 39.47, 42.26,
48.32, 51.10, 52.84, 53.17, 53.24, 53.40, 54.25, 55.17, 58.36, 120.67, 127.73, 127.91, 128.14, 128.25,
131.07, 139.12, 146.27, 168.78, 177.90, 177.98, 178.27, 178.60, 178.65, 178.76. LRMS (ESI-MS): m/z
calcd. for C36H50N8O152+, [M+2H]2+, 417.2, found 417.4.
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Metal Complexation
[Eu-MP9b]. MP9b (50 mg, 0.115 mmol) was dissolved in H2O (7 mL) and the pH of the solution
adjusted to 6 using 0.3 M HCl. Aqueous EuCl3 (0.2726 M, 422 L) was added and the solution was stirred
at room temperature overnight. The pH was raised to 10 by addition of 0.3 M NaOH causing excess Eu 3+
to precipitate as Eu(OH)3. The precipitate was removed by syringe filtration and the absence of free metal
was confirmed using a Xylenol Orange test. The pH of the solution was adjusted to 7 and lyophilized to
yield a white solid. LRMS (ESI-MS): m/z calcd. for C20H34EuN8O32+, M2+, 293.6, found 293.3.

[Tb-MP9b]. MP9b (101 mg, 0.232 mmol) was dissolved in H2O (7 mL) and the pH of the solution
adjusted to 6 using 0.3 M HCl. Aqueous TbCl3 (0.1332 M, 1745 L) was added and the solution was stirred
at room temperature overnight. The pH was raised to 10 by addition of 0.3 M NaOH causing excess Tb3+
to precipitate as Tb(OH)3. The precipitate was removed by syringe filtration and the absence of free metal
was confirmed using a Xylenol Orange test. The pH of the solution was adjusted to 7 and lyophilized to
yield a white solid. LRMS (ESI-MS): m/z calcd. for C20H34N8O3Tb2+, M2+, 296.6, found 296.3; calcd. for
C20H34N8O3Tb3+, M3+, 197.7, found 197.9.

[Tm-MP9b]. MP9b (50 mg, 0.115 mmol) was dissolved in H2O (7 mL) and the pH of the solution
adjusted to 6 using 0.3 M HCl. Aqueous TmCl3 (0.332 M, 350 L) was added and the solution was stirred
at room temperature overnight. The pH was raised to 10 by addition of 0.3 M NaOH causing excess Tm 3+
to precipitate as Tm(OH)3. The precipitate was removed by syringe filtration and the absence of free metal
was confirmed using a Xylenol Orange test. The pH of the solution was adjusted to 7 and lyophilized to
yield a white solid. LRMS (ESI-MS): m/z calcd. for C20H34N8O3Tm2+, M2+, 301.6, found 301.3; calcd. for
C20H34N8O3Tm3+, M3+, 201.1, found 201.2.

[Eu-MP13]. MP13 (106 mg, 0.175 mmol) was dissolved in H2O (7 mL) and the pH of the solution
adjusted to 6 using 0.3 M HCl. Aqueous EuCl3 (0.2726 M, 645 L) was added and the solution was stirred
at room temperature overnight. The pH was raised to 10 by addition of 0.3 M NaOH causing excess Eu 3+
to precipitate as Eu(OH)3. The precipitate was removed by syringe filtration and the absence of free metal
was confirmed using a Xylenol Orange test. The pH of the solution was adjusted to 7 and lyophilized to
yield a white solid. LRMS (ESI-MS): m/z calcd. for C26H40EuN8O92+, M2+, 380.6, found 380.3.

[Tb-MP13]. MP13 (106 mg, 0.175 mmol) was dissolved in H2O (7 mL) and the pH of the solution
adjusted to 6 using 0.3 M HCl. Aqueous TbCl3 (0.1332 M, 1314 L) was added and the solution was stirred
at room temperature overnight. The pH was raised to 10 by addition of 0.3 M NaOH causing excess Tb 3+
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to precipitate as Tb(OH)3. The precipitate was removed by syringe filtration and the absence of free metal
was confirmed using a Xylenol Orange test. The pH of the solution was adjusted to 7 and lyophilized to
yield a white solid. LRMS (ESI-MS): m/z calcd. for C26H40N8O9Tb2+, M2+, 383.6, found 383.2; calcd. for
C26H40N8O9Tb3+, M3+, 256.1, found 255.7.

[Tm-MP13]. MP13 (106 mg, 0.175 mmol) was dissolved in H2O (7 mL) and the pH of the solution
adjusted to 6 using 0.3 M HCl. Aqueous TmCl3 (0.332 M, 530 L) was added and the solution was stirred
at room temperature overnight. The pH was raised to 10 by addition of 0.3 M NaOH causing excess Tm 3+
to precipitate as Tm(OH)3. The precipitate was removed by syringe filtration and the absence of free metal
was confirmed using a Xylenol Orange test. The pH of the solution was adjusted to 7 and lyophilized to
yield a white solid. LRMS (ESI-MS): m/z calcd. for C26H40N8O9Tm2+, M2+, 388.6, found 388.3; calcd. for
C26H40N8O9Tm3+, M3+, 259.1, found 259.4.

[Eu-MP28]. MP28 (101 mg, 0.131 mmol) was dissolved in H2O (7 mL) and the pH of the solution
adjusted to 6 using 0.3 M HCl. Aqueous EuCl3 (0.2726 M, 480 L) was added and the solution was stirred
at room temperature overnight. The pH was raised to 10 by addition of 0.3 M NaOH causing excess Eu 3+
to precipitate as Eu(OH)3. The precipitate was removed by syringe filtration and the absence of free metal
was confirmed using a Xylenol Orange test. The pH of the solution was adjusted to 7 and lyophilized to
yield a white solid. LRMS (ESI-MS): m/z calcd. for C32H45EuN8O152+, [M+2H]2+, 467.1, found 467.3.

[Tb-MP28]. MP28 (101 mg, 0.131 mmol) was dissolved in H2O (7 mL) and the pH of the solution
adjusted to 6 using 0.3 M HCl. Aqueous TbCl3 (0.1332 M, 990 L) was added and the solution was stirred
at room temperature overnight. The pH was raised to 10 by addition of 0.3 M NaOH causing excess Tb 3+
to precipitate as Tb(OH)3. The precipitate was removed by syringe filtration and the absence of free metal
was confirmed using a Xylenol Orange test. The pH of the solution was adjusted to 7 and lyophilized to
yield a white solid. LRMS (ESI-MS): m/z calcd. for C32H45N8O15Tb2+, M2+, 470.2, found 470.6; calcd. for
C32H45N8O15Tb3+, M3+, 313.7, found 313.9.

[Tm-MP28]. MP28 (101 mg, 0.131 mmol) was dissolved in H2O (7 mL) and the pH of the solution
adjusted to 6 using 0.3 M HCl. Aqueous TmCl3 (0.332 M, 400 L) was added and the solution was stirred
at room temperature overnight. The pH was raised to 10 by addition of 0.3 M NaOH causing excess Tm 3+
to precipitate as Tm(OH)3. The precipitate was removed by syringe filtration and the absence of free metal
was confirmed using a Xylenol Orange test. The pH of the solution was adjusted to 7 and lyophilized to

89

yield a pale yellow solid. LRMS (ESI-MS): m/z calcd. for C32H45N8O15Tm2+, M2+, 475.6, found 475.1;
calcd. for C32H45N8O15Tm3+, M3+, 317.1, found 317.3.

[Eu-MP30]. MP30 (80 mg, 0.165 mmol) was dissolved in H2O (7 mL) and the pH of the solution
adjusted to 6 using 0.3 M HCl. Aqueous EuCl3 (0.2726 M, 610 L) was added and the solution was stirred
at room temperature overnight. The pH was raised to 10 by addition of 0.3 M NaOH causing excess Eu3+
to precipitate as Eu(OH)3. The precipitate was removed by syringe filtration and the absence of free metal
was confirmed using a Xylenol Orange test. The pH of the solution was adjusted to 7 and lyophilized to
yield a white solid. LRMS (ESI-MS): m/z calcd. for C24H36EuN8O32+, M2+, 318.6, found 318.3.

[Tb-MP30]. MP30 (80 mg, 0.165 mmol) was dissolved in H2O (7 mL) and the pH of the solution
adjusted to 6 using 0.3 M HCl. Aqueous TbCl3 (0.1332 M, 1240 L) was added and the solution was stirred
at room temperature overnight. The pH was raised to 10 by addition of 0.3 M NaOH causing excess Tb 3+
to precipitate as Tb(OH)3. The precipitate was removed by syringe filtration and the absence of free metal
was confirmed using a Xylenol Orange test. The pH of the solution was adjusted to 7 and lyophilized to
yield a white solid. LRMS (ESI-MS): m/z calcd. for C24H36N8O3Tb2+, M2+, 321.6, found 321.4; calcd. for
C24H36N8O3Tb3+, M3+, 214.4, found 214.7.

[Tm-MP30]. MP30 (50 mg, 0.103 mmol) was dissolved in H2O (7 mL) and the pH of the solution
adjusted to 6 using 0.3 M HCl. Aqueous TmCl3 (0.332 M, 315 L) was added and the solution was stirred
at room temperature overnight. The pH was raised to 10 by addition of 0.3 M NaOH causing excess Tm 3+
to precipitate as Tm(OH)3. The precipitate was removed by syringe filtration and the absence of free metal
was confirmed using a Xylenol Orange test. The pH of the solution was adjusted to 7 and lyophilized to
yield a white solid. LRMS (ESI-MS): m/z calcd. for C24H36N8O3Tm3+, M3+, 217.7, found 218.0; calcd. for
C24H36N8O3Tm2+, M2+, 326.6, found 326.3.

[Eu-MP33]. MP33 (99 mg, 0.151 mmol) was dissolved in H2O (7 mL) and the pH of the solution
adjusted to 6 using 0.3 M HCl. Aqueous EuCl3 (0.2726 M, 555 L) was added and the solution was stirred
at room temperature overnight. The pH was raised to 10 by addition of 0.3 M NaOH causing excess Eu 3+
to precipitate as Eu(OH)3. The precipitate was removed by syringe filtration and the absence of free metal
was confirmed using a Xylenol Orange test. The pH of the solution was adjusted to 7 and lyophilized to
yield a white solid. LRMS (ESI-MS): m/z calcd. for C30H42EuN8O92+, M2+, 270.4, found 270.7; calcd. for
C30H42EuN8O93+, M3+, 405.6, found 405.3.
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[Tb-MP33]. MP33 (99 mg, 0.151 mmol) was dissolved in H2O (7 mL) and the pH of the solution
adjusted to 6 using 0.3 M HCl. Aqueous TbCl3 (0.1332 M, 1135 L) was added and the solution was stirred
at room temperature overnight. The pH was raised to 10 by addition of 0.3 M NaOH causing excess Tb3+
to precipitate as Tb(OH)3. The precipitate was removed by syringe filtration and the absence of free metal
was confirmed using a Xylenol Orange test. The pH of the solution was adjusted to 7 and lyophilized to
yield a white solid. LRMS (ESI-MS): m/z calcd. for C30H42N8O9Tb2+, M2+, 408.6, found 408.4; calcd. for
C30H42N8O9Tb3+, M3+, 272.4, found 272.6.

[Tm-MP33]. MP33 (68 mg, 0.103 mmol) was dissolved in H2O (7 mL) and the pH of the solution
adjusted to 6 using 0.3 M HCl. Aqueous TmCl3 (0.332 M, 315 L) was added and the solution was stirred
at room temperature overnight. The pH was raised to 10 by addition of 0.3 M NaOH causing excess Tm 3+
to precipitate as Tm(OH)3. The precipitate was removed by syringe filtration and the absence of free metal
was confirmed using a Xylenol Orange test. The pH of the solution was adjusted to 7 and lyophilized to
yield a white solid. LRMS (ESI-MS): m/z calcd. for C30H42N8O9Tm3+, M3+, 275.7, found 276.1; calcd. for
C30H42N8O9Tm2+, M2+, 413.6, found 413.3.

[Eu-MP34]. MP34 (100 mg, 0.120 mmol) was dissolved in H2O (7 mL) and the pH of the solution
adjusted to 6 using 0.3 M HCl. Aqueous EuCl3 (0.2726 M, 445 L) was added and the solution was stirred
at room temperature overnight. The pH was raised to 10 by addition of 0.3 M NaOH causing excess Eu 3+
to precipitate as Eu(OH)3. The precipitate was removed by syringe filtration and the absence of free metal
was confirmed using a Xylenol Orange test. The pH of the solution was adjusted to 7 and lyophilized to
yield a golden-brown oil. LRMS (ESI-MS): m/z calcd. for C36H48EuN8O152+, M2+, 492.6, found 492.3;
calcd. for C36H48EuN8O153+, M3+, 328.4, found 328.7.

[Tb-MP34]. MP34 (100 mg, 0.120 mmol) was dissolved in H2O (7 mL) and the pH of the solution
adjusted to 6 using 0.3 M HCl. Aqueous TbCl3 (0.1332 M, 910 L) was added and the solution was stirred
at room temperature overnight. The pH was raised to 10 by addition of 0.3 M NaOH causing excess Tb 3+
to precipitate as Tb(OH)3. The precipitate was removed by syringe filtration and the absence of free metal
was confirmed using a Xylenol Orange test. The pH of the solution was adjusted to 7 and lyophilized to
yield a golden-brown oil. LRMS (ESI-MS): m/z calcd. for C36H48N8O15Tb2+, M2+, 495.6, found 495.2;
calcd. for C36H48EuN8O15Tb3+, M3+, 330.4, found 330.7.

[Tm-MP34]. MP34 (100 mg, 0.120 mmol) was dissolved in H2O (7 mL) and the pH of the solution
adjusted to 6 using 0.3 M HCl. Aqueous TmCl3 (0.332 M, 365 L) was added and the solution was stirred
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at room temperature overnight. The pH was raised to 10 by addition of 0.3 M NaOH causing excess Tm3+
to precipitate as Tm(OH)3. The precipitate was removed by syringe filtration and the absence of free metal
was confirmed using a Xylenol Orange test. The pH of the solution was adjusted to 7 and lyophilized to
yield a golden-brown oil. LRMS (ESI-MS): m/z calcd. for C36H48N8O15Tm2+, M2+, 500.6, found 500.1;
calcd. for C36H48EuN8O15Tm3+, M3+, 333.8, found 333.9.

Absorbance Measurements
Absorbance spectra were acquired at room temperature using a 1.0 cm quartz cuvette over a 200800 nm range with a 5 nm slit. Solutions of each lanthanide complex were prepared at 0.00625 mM using
0.1 mM HEPES buffer (pH 7.4).

Acquisition of Emission Spectra
Solutions of each lanthanide complex were prepared at 0.1 mM using 0.1 mM HEPES buffer (pH
7.4). A 450 nm long pass filter was used to eliminate second order peaks by removing longer
wavelengths. Spectra were recorded at room temperature using a 1.0 cm quartz cell and an excitation
monochromator slit width of 2 nm. Emission spectra of the Eu3+ and Tb3+complexes were acquired from
570-750 nm and 450-600 nm, respectively. Individual complexes were excited at the ex listed in Table 31.

Table 3-1. Excitation wavelengths of each compound acquired with an emission monochromator slit
width of 2 nm.
Compound

Eu-MP9

Eu-MP13

Eu-MP28

Eu-MP30

Eu-MP33

Eu-MP34

ex (nm)

272

272

274

322

320

320

Compound

Tb-MP9

Tb-MP13

Tb-MP28

Tb-MP30

Tb-MP33

Tb-MP34

ex (nm)

271

272

272

318

319

321

Acquisition of Excitation Spectra
Solutions of each lanthanide complex were prepared at 0.1 mM using 0.1 mM HEPES buffer (pH
7.4). A 450 nm long pass filter was used to eliminate second order peaks. Spectra were recorded at room
temperature using a 1.0 cm quartz cell and an emission monochromator slit width of 2 nm. Excitation
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spectra of all complexes were acquired from 200-450 nm. Individual spectra were acquired using the em
indicated in Table 3-2.

Table 3-2. Emission wavelengths of each compound acquired with an excitation monochromator slit
width of 2 nm.
Compound

Eu-MP9

Eu-MP13

Eu-MP28

Eu-MP30

Eu-MP33

Eu-MP34

em (nm)

612

613

613

636

633

633

Compound

Tb-MP9

Tb-MP13

Tb-MP28

Tb-MP30

Tb-MP33

Tb-MP34

em (nm)

564

564

564

564

564

564

Lifetime Measurements
Samples were prepared by lyophilizing aliquots of each lanthanide solution in 500 L of 0.1 mM
HEPES buffer (pH 7.4). One aliquot of each lanthanide solution was then redissolved in D 2O and
lyophilized. These samples were dissolved once more in D 2O and lyophilized. Solutions at 0.02 mM
concentrations were made by dissolving the compounds in HEPES buffer or D 2O. Phosphorescent decay
by delay measurements were acquired using a flash count of 50, sample window of 0.2 ms, 0.05 ms delay
increment, 5 ms max delay, and an initial delay of 0.05 ms. The intensity versus time data was fit with a
monoexponential decay to obtain  values. The number of bound water molecules (q) was determined using
equations 1 and 2 where x represents the number of amide protons in each complex.39

𝑞𝐸𝑢 = 1.2[(𝑘𝐻2 𝑂 − 𝑘𝐷2𝑂 ) − 0.25 − 0.075𝑥]

(1)

𝑞𝑇𝑏 = 5[(𝑘𝐻2 𝑂 − 𝑘𝐷2𝑂 ) − 0.06]

(2)

Quantum Yield () Measurements
Absorbance spectra were acquired between 200-800 nm at room temperature, using a 1.0 cm quartz
cuvette and a 5 nm slit width. Solutions of each lanthanide complex were prepared using 0.1 mM HEPES
buffer (pH 7.4) such that their absorbance intensities at 315 nm fell between 0.005 and 0.05. Emission
spectra were acquired upon excitation at 315 nm with collection from 570-750 nm for Eu3+ compounds and
450-600 nm for Tb3+ compounds. Areas under the emission curves versus absorbance intensities at 315 nm
were graphed and fit with a linear equation. These plots were compared with data acquired in a similar
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manner for reference compounds with known quantum yields. Rhodamine 101 in ethanol ( = 1) and
fluorescein in 0.1 M NaOH ( = 0.93) were used as reference compounds for Eu3+ and Tb3+ complexes,
respectively.40,41 Equation 3 was used to determine the quantum yield value of each complex where R
denotes values corresponding to the reference compound, x corresponds to the unknown sample
measurements, m represents the slope from the linear fit of the area under the emission curve versus
absorbance intensity, and n is the refractive index of the solvent used.42

𝑚

𝑛

Φ𝑥 = Φ𝑅 (𝑚𝑥 )(𝑛𝑥 )2
𝑅
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𝑅

(3)

3.3 Results and Discussion
Absorption Properties of the Tb3+ and Eu3+ Complexes
Absorption spectra were acquired for each complex to better understand how changes to the antenna,
ligand side-chains, and metal center affected the photophysical properties of the Tb3+ and Eu3+ complexes.
It was hypothesized that replacement of the pyridine antenna with a quinoline antenna would alter the
absorption characteristics of each complex based on previous work with similar chromophores. 43,44 The
quinoline antenna exhibits more conjugation so longer wavelengths of absorption are expected. Normalized
absorption spectra are shown in Figure 3-6. Absorption in the 250-350 nm range was analyzed as this is the
region in which  → * and n → * transitions are typically observed for pyridine and quinoline
compounds.43,45
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Figure 3-6. Normalized absorption spectra of 0.0625 mM Tb3+ and Eu3+ complexes in 0.1 M HEPES
buffer (pH 7.4). (a) and (b) correspond to the Tb3+ and Eu3+ pyridine complexes, respectively; (c) and (d)
correspond to the Tb3+ and Eu3+ quinoline complexes, respectively. Spectra were acquired at room
temperature from 200-800 nm.
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All absorption spectra were found to exhibit similar broad shapes, with the pyridine-containing
complexes (Figure 3-6a, b) having maximum wavelengths between 271 and 274 nm and those with
quinoline antenna (Figure 3-6c, d) displaying two peak wavelengths between 300 and 325 nm. These bands
are attributed to  → * electronic transitions of each antenna.45 For both the pyridine and quinoline
complexes, maximum wavelengths of absorption were very similar regardless of ligand side-chain identity.
This indicates that the different ligand side-chains have very little influence on the absorption properties of
each complex. Additionally, only minor variations in the overall shapes of the absorption spectra were
observed for the different complexes of the same ligand. This also suggests that metal ion identity has a
minimal effect on the absorption characteristics of lanthanide complexes of the same ligand.

Evaluation of Excitation Properties
Excitation spectra were acquired to evaluate the energy needed to excite electrons from the singlet
ground state to the singlet excited state of the pyridine and quinoline chromophores.46 Following
intersystem crossing from the singlet excited state to the triplet excited state of the antenna, some of the
energy absorbed by the antenna is transferred to the Ln 3+ excited states.46 Following rapid internal
conversion to the emitting level of the lanthanide ion, sharp emission lines, characteristic of the metal
center, are emitted.47 The excitation spectra for all complexes are shown in Figure 3-7.
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Figure 3-7. Normalized excitation spectra of 0.1 mM complexes in 0.1 mM HEPES buffer (pH 7.4). (a)
and (b) correspond to the Tb3+ and Eu3+ pyridine complexes, respectively; (c) and (d) correspond to the
Tb3+ and Eu3+ quinoline complexes, respectively. Spectra were acquired at room temperature from 200450 nm with an emission monochromator slit width of 2 nm. em values used to acquire each spectrum
and maximum wavelengths of excitation can be found in Table 3-3.
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Table 3-3. Emission and excitation wavelengths of each complex.
Complex
Eu-MP9b
Eu-MP13
Eu-MP28
Tb-MP9b
Tb-MP13
Tb-MP28
Eu-MP30
Eu-MP33
Eu-MP34
Tb-MP30
Tb-MP33
Tb-MP34

em
612
613
613
564
564
564
636
633
633
564
564
564

ex
272
272
274
271
272
272
322
320
320
318
319
321

The maximum excitation wavelengths between 271-274 nm for pyridine complexes and 319-322
nm for quinoline complexes are reflective of  → * electronic transitions.45 This variation in the maximum
excitation wavelengths between pyridine and quinoline containing complexes is consistent with the
expectation that the higher conjugation in the quinoline should result in a decrease in energy of the  → *
electronic transitions. The difference in maximum excitation wavelengths for all complexes with the same
metal center and antenna was found to be less than 3 nm, thus suggesting that changing the ligand sidechains had little effect on the excitation properties of each complex. This minimal effect of ligand sidechain identity was also reflected in the shape similarities of the excitation spectra and consistent with the
absorption spectroscopy data.

Evaluation of Emission Properties
The emission spectra of all complexes can be found in Figure 3-8. All spectra display characteristic
emission profiles of Tb3+ and Eu3+ complexes. For the Tb3+ complexes, sharp emission peaks from 5D4 →
7FJ,

where J = 6, 5, 4, 3, can be observed between 475-630 nm, with the most intense emission peak located

at 545 nm.48 For the Eu3+ complexes, narrow emission bands from 5D0-7FJ, where J = 0-4, can be observed
between 598-717 nm, with the most intense emission peak located at approximately 615 nm.49
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Figure 3-8. Emission spectra of 1 x 10-4 M Tb3+ and Eu3+ complexes in 0.1 M HEPES buffer (pH 7.4). (a)
and (b) correspond to Tb3+ and Eu3+ pyridine complexes, respectively; (c) and (d) correspond to Tb3+ and
Eu3+ quinoline complexes. Emission spectra of Eu3+ and Tb3+ were acquired upon excitation at (a) 271
nm, (b) 272 nm, (c) 319 nm, and (d) 320 nm using 2 nm slit widths.

The emission intensities and peak shapes of the terbium complexes can be attributed to the ligandfield-induced changes in the transition processes.50 For Tb3+ complexes, the peak at approximately 485 nm
is most susceptible to the ligand environment and does show a change in intensity with varying ligand
identity.50 Furthermore, the sharp peak at approximately 545 nm is indicative of the ability of each Tb 3+
complex to emit green light.50 The shape and linewidth of this peak at 545 nm is the same for all complexes,
indicating that Tb3+ occupies a similar symmetry in all complexes.51 Tb-MP9, Tb-MP13, and Tb-MP28
have higher emission intensities than Tb-MP30, Tb-MP33, and Tb-MP34, which suggests that the pyridine
antenna is a more effective sensitizer of Tb3+ luminescence.51,52

99

For the Eu3+ complexes, the identity of the antenna is clearly affecting the properties of the observed
emission bands. In particular, the J = 0 and J = 2 bands at 580 nm and 615 nm, respectively, indicate
structural and photophysical properties of each of the europium complexes. For Eu3+ complexes, the
hypersensitive J = 2 band at 615 nm is also primarily responsible for the red color observed upon
excitation.53 There appears to be distinct splitting of this band at 615 nm for all complexes, which can be
indicative of two components for the 5D0 → 7F2 transition.53 The splitting of the hypersensitive band at 615
nm is more pronounced for Eu-MP30, Eu-MP33, and Eu-MP34, which corresponds to a higher level of
asymmetry for those complexes with quinoline antennae than those with pyridine antennae.53 The J = 0
band at 580 nm is typically weak and forbidden by the Judd-Ofelt theory.53 The sharp peak seen in the
emission spectra at 580 nm corresponds to a Cnv, Cn, or Cs point group for all Eu3+ complexes.53

Eu3+ and Tb3+ complexes with MP13, MP28, MP33, and MP34 ligands consistently displayed
higher emission intensities than those with MP9b and MP30 ligands. This observation can be attributed to
the presence of twice the amount of amide groups in the MP9b and MP30 ligands. N-H groups cause a
deactivation of the luminescence of lanthanide complexes through vibrational energy transfer and a larger
number of these groups will cause a larger loss in emission intensity.39 This quenching effect results in the
lower emission intensities for the MP9b and MP30 complexes and is observed regardless of the identity of
the antenna.39

Quantum Yields and q-values
Quantum yield is a measure of the ratio of emitted photons to absorbed photons.54 It is therefore a
measurement of the probability that an excited photon will emit light as it relaxes to equilibrium. The overall
quantum yield also takes into account the energy transfer efficiency from the antenna to the lanthanide ion
as not all energy absorbed by an antenna will be transferred to the metal center. 54 Quantum yields were
determined using previously published methods.42 The calculated quantum yield values for each complex
can be found in Table 3-4.

One factor that greatly influences quantum yield values is the energy difference between the triplet
excited state of the antenna and the emitting level of the lanthanide ion.50 If the energy difference between
the two levels is too large, energy cannot be transferred from the ligand to the metal center and no emission
will occur.50 However, if the energy difference is too small, the energy will be transferred back to the
antenna instead of emitting from the lanthanide ion.50,55 Tb-MP9b, Tb-MP13, and Tb-MP28 exhibited
quantum yield values that were an order of magnitude higher than all other complexes. This demonstrates
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that the pyridine antenna has the best photophysical properties for effective sensitization of Tb 3+
luminescence. This observation is supported by previous studies which have shown that pyridine-based
antennae enhanced the emission intensities of Tb3+ complexes more than 104-fold.37 Likewise, the quantum
yields of Eu-MP30, Eu-MP33, and Eu-MP34 are twice as large as those of Eu-MP9b, Eu-MP13, and EuMP28. Similarly, this suggests that the quinoline antenna is a better sensitizer of the luminescence of Eu 3+
than pyridine moieties. Sensitization of the luminescence of Eu3+ via ligand-to-Eu3+ energy transfer has
been shown to occur when the ligand triplet state is located below 24000 cm-1 while for Tb3+, the ligand
triplet state should be higher in energy.50 The emitting level of Eu3+ also lies lower than that of Tb3+, thus,
the triplet excited state energy level of an efficient sensitizer for Eu3+ does not usually have the same ability
to sensitize the luminescence of Tb3+.56

Table 3-4. Lifetime measurement and q values of 0.02 mM complexes in 0.1 mM HEPES buffer (pH
7.4) and D2O. Calculated quantum yield values of Eu3+ and Tb3+ complexes prepared in 0.1 mM HEPES
buffer (pH 7.4) using Rhodamine 101 in ethanol ( = 1) and Fluorescein in 0.1 M NaOH ( = 0.93) as a
reference at 315 nm, respectively.40,41
Complex

 D2O

 H2O

k D2O

k H2O

q value

Quantum
Yield ()

Eu-MP9b

2.02

0.525

0.494

1.90

0.853a

0.0183

Eu-MP13

2.17

0.618

0.462

1.62

0.818a

0.0264

Eu-MP28

2.41

0.600

0.416

1.67

0.930a

0.0229

Tb-MP9b

4.43

2.38

0.226

0.421

0.676b

0.329

Tb-MP13

5.98

2.53

0.167

0.396

0.844b

0.355

Tb-MP28

4.90

2.29

0.204

0.437

0.864b

0.394

Eu-MP30

1.95

0.546

0.514

1.83

0.743a

0.0436

Eu-MP33

2.18

0.581

0.459

1.72

0.944a

0.0606

Eu-MP34

2.27

0.586

0.440

1.71

0.949a

0.0561

Tb-MP30

1.95

0.546

0.514

1.83

0.743a

0.0128

Tb-MP33

2.18

0.581

0.459

1.72

0.944a

0.0155

Tb-MP34

2.27

0.586

0.440

1.71

0.949a

0.0196

aThe

number of bound water molecules, q, for Eu3+ complexes was calculated using the equation
𝑞 = 1.2[(𝑘𝐻2 𝑂 − 𝑘𝐷2 𝑂 ) − 0.25 − 0.075𝑥] where x is the number of amide protons in each complex.
bThe

number of bound water molecules, q, for Tb3+ was calculated using the equation
𝑞 = 5[(𝑘𝐻2 𝑂 − 𝑘𝐷2 𝑂 ) − 0.06]
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Complexes with MP13, MP28, MP33, and MP34 ligands have higher quantum yields than MP9b
and MP30 ligands which contain acetamide groups. As previously mentioned, the amide groups on the
acetamide side-chains quench lanthanide ion emission through vibrational energy transfer. 39 As quantum
yield is related to emission intensity, it is logical that those complexes with more amide groups will have
both lower emission intensities and quantum yield values.

The long-lived luminescence lifetimes exhibited by Eu3+ and Tb3+ make these lanthanides ideal for
time-resolved detection as they allow for the acquisition of signal after background autofluorescence has
subsided.57,58 Using luminescence lifetime values, the number of bound water molecules can be calculated
through comparison of the luminescence signal decay in both D2O and H2O. Water quenches luminescence
intensity due to its O-H oscillating groups while the O-D oscillator in D2O has negligible effect.47 This
allows for the rates of decay in each solvent to be related to the number of lanthanide-bound water molecules
through the Horrocks equation.39 The measured luminescence lifetime values for each complex and their
calculated q values can be found in Table 3-4. As expected, the luminescence lifetime of each complex in
water is shorter than that in D2O. This is due to the quenching effects of O-H oscillators of H2O that are not
present in D2O. The calculated q values are indicative of one bound water molecule for each complex and
this is consistent with the expected nine-coordinate geometry of Eu3+ and Tb3+.59

Original measurements of Tb-MP30, Tb-MP33, and Tb-MP34 lifetimes were challenging and
yielded q values that were either negative or significantly larger than expected for a Tb 3+ ion chelated by
an octadentate ligand. These abnormal values may be due to thermal back transfer from the lanthanide ion
to the quinoline chromophore. As previously stated, thermal back energy transfer can occur when the ligand
triplet state energy is too close to that of the metal ion.50,55 The quinoline antennae have been shown through
quantum yield measurements to be more effective sensitizers of Eu3+ luminescence and may not have a
high enough triplet state energy level to participate in ligand-to-metal energy transfer with Tb3+. This can
therefore facilitate easy transfer from the metal ion back to the antenna, which could complicate
measurements of luminescence lifetimes. Nonetheless, the q-values obtained for the Eu3+ complexes were
used to extrapolate the number of bound water molecules in the Tb 3+ complexes since the europium and
terbium complexes are isostructural.59 A similar trend can be seen between the q values calculated for the
Eu3+ and Tb3+ complexes with pyridine antenna, which all appear to have one bound water molecule.
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PARACEST studies
In addition to their optical imaging capabilities, paramagnetic lanthanide complexes have the potential
to produce MR contrast. MR contrast can be produced through the chemical exchange of protons on the
lanthanide complex with protons of surrounding bulk water by a process known as Chemical Exchange
Saturation Transfer (CEST).60–62 To evaluate a lanthanide complex’s CEST abilities, CEST spectra are
acquired by varying irradiation frequency and measuring the change in water proton MR signal intensity.60–
62

These spectra can be used to determine if a lanthanide complex has favorable properties for detection via

CEST imaging.63 CEST spectra acquired at 298 K and 310 K for the Eu3+ complexes with appended pyridine
moieties are shown in Figure 3-9.

The large peak at 0 ppm reflects the direct saturation at the bulk water frequency. 63,64 The smaller
peaks shifted to the left of this 0 ppm peak are signal reductions due to the exchange of the Eu 3+-bound
water molecule with bulk water.64 For a PARACEST agent to have adequate CEST properties for imaging,
it is important for these additional peaks to be shifted as far away as possible from the saturated water peak.
The exchange rate (kex) must also be lower than the chemical shift difference () between the two
exchanging pools of water or protons.65 Paramagnetic chelates are of particular interest for CEST imaging
as  is much larger in these chelates than in diamagnetic compounds.65 A larger  not only ensures that
selectively saturating bound water protons does not result in the direct saturation of bulk water protons, but
also allows the use of PARACEST agents with faster exchange rates.66,67

In the CEST spectra acquired at 298 K, all complexes show two peaks shifted from the saturated water
peak with a more prominent signal at approximately 40 ppm and a small shoulder shifted 10-15 ppm further.
Exact values of these peaks for each complex can be found in Table 3-5. These shifted peaks correspond to
exchange between bulk water protons and Eu3+-bound water molecules and is consistent with the fact that
each complex has one bound water molecule regardless of ligand identity. In previous studies of Eu 3+DOTA-tetraamide complexes, peaks located at approximately 50 ppm have been attributed to exchange
between bound and bulk water molecules.68 Similar signals at ~50 ppm have been observed for Eu-DOTA
complexes with appended glycinamide groups.68,69 The presence of two peaks with similar chemical shifts
may be indicative of two different SAP isomers in solution with the peak at approximately 40 ppm
exhibiting higher CEST signal than the other.
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Figure 3-9. CEST spectra of Eu3+ (10 mM) acquired at 9.4 T, 298 K (Figure a) and 310 K (Figure b).
Spectra were acquired at pH = 7, B1 = 18.8 μT, and irradiation time = 5 s.

The broad nature of the Eu-MP9b peak also indicates that water exchange in the complex is faster
compared to Eu-MP13 and Eu-MP28. Carboxylate groups have been shown to decrease water exchange
rates by establishing hydrogen bond networks that stabilize the bound water molecule and therefore hinder
access to other water molecules.32,70 The presence of carboxylate groups in Eu-MP13 and Eu-MP28 could
therefore be responsible for narrower CEST peaks for these complexes compared to Eu-MP9b. Eu-MP9b
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also displayed the largest CEST intensity and this can be attributed to the fact that it has more exchangeable
amide protons in comparison to the other complexes. The presence of more amide protons has been shown
to result in a greater decrease in bulk water signal.62 Additionally, the absence of carboxylate groups in this
complex allows for easier access of the lanthanide ion center to exchanging water molecules and therefore
results in more saturation transfer to the bulk water.

Table 3-5. CEST exchange peaks for the Eu3+-pyridine complexes.

Complex
Eu-MP9b
Eu-MP13
Eu-MP28

298 K
Main peak
Secondary
(ppm)
peak (ppm)
42
53
42
54
43
54

310 K
Main peak
Secondary
(ppm)
peak (ppm)
38
39
40
50

Increasing the temperature to 310 K resulted in the elimination of the secondary peaks for Eu-MP9b
and Eu-MP13. The main peaks at approximately 40 ppm broadened with increasing temperature for EuMP9 and Eu-MP13. At higher temperatures, CEST peaks of various Eu 3+ complexes have been found to
broaden and shift upfield toward the bulk water resonance.27 The broadening of the peaks is indicative of
an increasing exchange rate which occurs as temperature increases according to the Arrhenius equation. 64,62
The secondary peak of Eu-MP28 is still present, though with a lower intensity. This suggests that water
exchange in this complex is still slow enough to produce an observable CEST signal. Furthermore, the
intensity of the main peak at 40 ppm increased at higher temperature, which is indicative of Eu-MP28
having more ideal CEST capabilities at 310 K. However, once the optimum temperature has been exceeded,
the CEST peak is expected to become even broader, shift closer toward the bulk water peak, and
significantly decrease in intensity.62

3.4 Conclusion
A library of Eu3+ and Tb3+ complexes was successfully synthesized and the effect of ligand sidechains on the optical and magnetic resonance imaging properties of these complexes was evaluated. Ligand
identity was found to have little effect on the absorption and excitation properties of the complexes but
significantly impacted the emission intensities and quantum yield values of the complexes in this study.
Complexes of the MP9b and MP30 ligands consistently displayed lower quantum yield values and this was
attributed to the quenching of the emission intensity brought about by the additional amide groups in their
side-chains. All complexes were found to possess one bound water molecule coordinated to the metal center
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which allowed the investigation of their PARACEST MRI properties. Eu-MP9b exhibited the broadest
CEST peaks and largest CEST signals. These characteristics were attributed to the faster water exchange
kinetics of this complex. Eu-MP13 and Eu-MP28 displayed sharper and less intense peaks at both 298 K
and 310 K due to hydrogen-bond networks formed by the carboxylate groups in the ligand side-chains. The
presence of these networks caused a deceleration of the water exchange rates in these complexes and a
resultant decrease in CEST effect. The CEST signal of Eu-MP28 was found to increase at higher
temperature thus suggesting that this complex may have optimal exchange kinetics at physiological
temperatures.

3.5 Future Work
The initial goal of this project was to determine if the incorporation of a bulky pyridine or quinoline
moiety would favor the adoption of the TSAP geometry in solution. To evaluate the ratio of TSAP and SAP
isomers in solution, 1H NMR is typically used to distinguish each isomer by its unique chemical shift.24,71
This particular goal was not met due to instrumentation limitations. We hope to be able to perform this
experiment in the near future in order to test the above hypothesis. Since faster proton exchange rates
associated with the TSAP isomer has been shown to overcome the loss of CEST signal through the T2ex
mechanism, we believe that designing agents that preferentially adopt the TSAP geometry, and produce
CEST signal through amide proton exchange, would result in PARACEST agents that can be utilized for
in vivo applications.12
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Appendix A. Supporting Data
A.1 NMR Spectra

Figure A-1. 1H NMR spectrum of OME-2 in CDCl3.
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Figure A-2. 1H NMR spectrum of OME-3 in CDCl3.

Figure A-3. 1H NMR spectrum of OME-4 in CDCl3.
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Figure A-4. 1H NMR spectrum of OME-5 in CDCl3.

Figure A-5. 1H NMR spectrum of OME-6 in CDCl3.
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Figure A-6. 1H NMR spectrum of OME-7 in CDCl3.

Figure A-7. 1H NMR spectrum of OME-8 in CDCl3.
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Figure A-8. 1H NMR spectrum of MP-27 in CDCl3.

Figure A-9. 13C NMR spectrum of MP-27 in CDCl3.
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Figure A-10. 1H NMR spectrum of MP-24 in CDCl3.

Figure A-11. 13C NMR spectrum of MP-24 in CDCl3.
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Figure A-12. 1H NMR spectrum of MP-38 in CDCl3.

Figure A-13. 13C NMR spectrum of MP-38 in CDCl3.
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Figure A-14. 1H NMR spectrum of MP-25 in CDCl3.

Figure A-15. 13C NMR spectrum of MP-25 in CDCl3.
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Figure A-16. 1H NMR spectrum of MP-40 in CDCl3.

Figure A-17. 13C NMR spectrum of MP-40 in CDCl3.
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Figure A-18. 1H NMR spectrum of MP-39 in CDCl3.

Figure A-19. 13C NMR spectrum of MP-39 in CDCl3.
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Figure A-20. 1H NMR spectrum of MP-26 in CDCl3.

Figure A-21. 13C NMR spectrum of MP-26 in CDCl3.
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Figure A-22. 1H NMR spectrum of MP-41 in CDCl3.

Figure A-23. 13C NMR spectrum of MP-41 in CDCl3.
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Figure A-24. 1H NMR spectrum of MP-30 in D2O.

Figure A-25. 13C NMR spectrum of MP-30 in D2O.
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Figure A-26. 1H NMR spectrum of MP-42 in D2O.

Figure A-27. 13C NMR spectrum of MP-42 in D2O.
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Figure A-28. 1H NMR spectrum of MP-43 in D2O.

Figure A-29. 13C NMR spectrum of MP-43 in D2O.
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Figure A-30. 1H NMR spectrum of MP-44 in D2O.

Figure A-31. 13C NMR spectrum of MP-44 in D2O.
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Figure A-32. 1H NMR spectrum of MP-45 in D2O.

Figure A-33. 13C NMR spectrum of MP-45 in D2O.
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Figure A-34. 1H NMR spectrum of MP-46 in D2O.

Figure A-35. 13C NMR spectrum of MP-46 in D2O.
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Figure A-36. 1H NMR spectrum of MP-47 in D2O.

Figure A-37. 13C NMR spectrum of MP-47 in D2O.
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Figure A-38. 1H NMR spectrum of MP-48 in D2O.

Figure A-39. 13C NMR spectrum of MP-48 in D2O.
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Figure A-40. 1H NMR of MP3 taken in CDCl3

Figure A-41. 13C NMR of MP3 taken in CDCl3
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Figure A-42. 1H NMR of MP15 taken in CDCl3

Figure A-43. 13C NMR of MP15 taken in CDCl3
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Figure A-44. 1H NMR of MP1 taken in CDCl3

Figure A-45. 13C NMR of MP1 taken in CDCl3
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Figure A-46. 1H NMR of MP9 taken in D2O

Figure A-47. 13C NMR of MP9 taken in D2O
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Figure A-48. 1H NMR of MP8 taken in CDCl3

Figure A-49. 13C NMR of MP8 taken in CDCl3
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Figure A-50. 1H NMR of MP13 taken in D2O

Figure A-51. 13C NMR of MP13 taken in D2O
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Figure A-52. 1H NMR of MP19 taken in CDCl3

Figure A-53. 13C NMR of MP19 taken in CDCl3
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Figure A-54. 1H NMR of MP28 taken in D2O

Figure A-55. 13C NMR of MP28 taken in D2O
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Figure A-56. 1H NMR of MP27 taken in CDCl3

Figure A-57. 13C NMR of MP27 taken in CDCl3
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Figure A-58. 1H NMR of MP31 taken in CDCl3

Figure A-59. 13C NMR of MP31 taken in CDCl3
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Figure A-60. 1H NMR of MP33 taken in D2O

Figure A-61. 13C NMR of MP33 taken in D2O
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Figure A-62. 1H NMR of MP32 taken in CDCl3

Figure A-63. 13C NMR of MP32 taken in CDCl3
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Figure A-64. 1H NMR of MP34 taken in D2O

Figure A-65. 13C NMR of MP34 taken in D2O
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A.2 HPLC Methods and Chromatograms
HPLC Methods. HPLC analyses were performed with an Agilent Technologies 1100 system.
Method A. Solvent A = 0.1% TFA in Water, Solvent B = 0.1% TFA in Acetonitrile, Flow Rate = 0.2
mL/min, Column = Kinetex 2.6µm XB-C18 100 Å, HPLC Column 150 x 4.6 mm. 0-1 min (5% B), 1-11
min (5% B to 8% B)
Method B. Solvent A = 0.1% TFA in Water, Solvent B = 0.1% TFA in Acetonitrile, Flow Rate = 0.5
mL/min, Column = Phenomenex Luna® 5 µm C18(2) 100 Å, LC Column 150 x 4.6 mm. 0-2 min (5% B),
2-10 min (5% B to 30% B), 10-11 min (30% B)
Method C. Solvent A = 0.1% TFA in Water, Solvent B = 0.1% TFA in Acetonitrile, Flow Rate = 0.5
mL/min, Column = Phenomenex Luna® 5 µm C18(2) 100 Å, LC Column 150 x 4.6 mm. 0-2 min (5% B),
2-10 min (5% B to 20% B), 10-11 min (30% B)
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Figure A-66. HPLC chromatogram of MP30 acquired with Method A at 254 nm.
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Figure A-67. HPLC chromatogram of MP42 acquired with Method A at 254 nm.
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Figure A-68. HPLC chromatogram of MP43 acquired with Method A at 254 nm.
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Figure A-69. HPLC chromatogram of MP44 acquired with Method A at 254 nm.
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Figure A-70. HPLC chromatogram of MP45 acquired with Method A at 254 nm.
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Figure A-71. HPLC chromatogram of MP46 acquired with Method A at 254 nm.
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Figure A-72. HPLC chromatogram of MP47 acquired with Method A at 254 nm.
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Figure A-73. HPLC chromatogram of MP48 acquired with Method A at 254 nm.
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Figure A-74. HPLC chromatogram of Eu-MP30 acquired with Method B at 254 nm.
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Figure A-75. HPLC chromatogram of Eu-MP42 acquired with Method B at 254 nm.

150

800

mAu

600
400
200
0
0

2

4

6

8

10

Retention Time (min)

Figure A-76. HPLC chromatogram of Eu-MP43 acquired with Method B at 254 nm.
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Figure A-77. HPLC chromatogram of Eu-MP44 acquired with Method B at 254 nm.
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Figure A-78. HPLC chromatogram of Eu-MP45 acquired with Method B at 254 nm.
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Figure A-79. HPLC chromatogram of Eu-MP46 acquired with Method B at 254 nm.
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Figure A-80. HPLC chromatogram of Eu-MP47 acquired with Method B at 254 nm.
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Figure A-81. HPLC chromatogram of Eu-MP48 acquired with Method B at 254 nm.
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Figure A-82. HPLC chromatogram of MP9b acquired with Method A at 254 nm.
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Figure A-83. HPLC chromatogram of MP13 acquired with Method A at 254 nm.
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Figure A-84. HPLC chromatogram of MP28 acquired with Method A at 254 nm.
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Figure A-85. HPLC chromatogram of MP33 acquired with Method A at 254 nm.
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Figure A-86. HPLC chromatogram of MP34 acquired with Method A at 254 nm.
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Figure A-87. HPLC chromatogram of Eu-MP9b acquired with Method B at 254 nm.
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Figure A-88. HPLC chromatogram of Eu-MP13 acquired with Method C at 254 nm.
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Figure A-89. HPLC chromatogram of Eu-MP28 acquired with Method B at 254 nm.

157

mAu

60

40

20

0
0

2

4

6

8

10

Retention Time (min)

Figure A-90. HPLC chromatogram of Eu-MP33 acquired with Method B at 254 nm.
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Figure A-91. HPLC chromatogram of Eu-MP34 acquired with Method B at 254 nm.
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Figure A-92. HPLC chromatogram of Tb-MP9 acquired with Method B at 254 nm.
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Figure A-93. HPLC chromatogram of Tb-MP13 acquired with Method B at 254 nm.
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Figure A-94. HPLC chromatogram of Tb-MP28 acquired with Method B at 254 nm.
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Figure A-95. HPLC chromatogram of Tb-MP30 acquired with Method B at 254 nm.
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Figure A-96. HPLC chromatogram of Tb-MP33 acquired with Method B at 254 nm.
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Figure A-97. HPLC chromatogram of Tb-MP34 acquired with Method B at 254 nm.
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Figure A-98. HPLC chromatogram of Tm-MP9 acquired with Method B at 254 nm.
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Figure A-99. HPLC chromatogram of Tm-MP13 acquired with Method B at 254 nm.
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Figure A-100. HPLC chromatogram of Tm-MP28 acquired with Method B at 254 nm.
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Figure A-101. HPLC chromatogram of Tm-MP30 acquired with Method B at 254 nm.
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Figure A-102. HPLC chromatogram of Tm-MP33 acquired with Method B at 254 nm.
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Figure A-103. HPLC chromatogram of Tm-MP34 acquired with Method B at 254 nm.
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A.3 Phosphorescence Spectra

Normalized Emisison
Intensity

1.0
0.8
0.6
0.4
0.2
0.0
500

550

600

650

700

Wavelength (nm)
Figure A-104. Phosphorescence emission spectrum of Gd-MP30 (1 mM) in 10 mM HEPES buffer (pH 7)
acquired with ex = 309 nm.
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Figure A-105. Phosphorescence emission spectrum of Gd-MP42 (1 mM) in 10 mM HEPES buffer (pH 7)
acquired with ex = 322 nm.
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Figure A-106. Phosphorescence emission spectrum of Gd-MP43 (1 mM) in 10 mM HEPES buffer (pH 7)
acquired with ex = 326 nm.

Normalized Emisison
Intensity

1.0
0.8
0.6
0.4
0.2
0.0
500

550

600

650

700

Wavelength (nm)

Figure A-107. Phosphorescence emission spectrum of Gd-MP44 (1 mM) in 10 mM HEPES buffer (pH 7)
acquired with ex = 350 nm.
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Figure A-108. Phosphorescence emission spectrum of Gd-MP45 (1 mM) in 10 mM HEPES buffer (pH 7)
acquired with ex = 320 nm.
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Figure A-109. Phosphorescence emission spectrum of Gd-MP46 (1 mM) in 10 mM HEPES buffer (pH 7)
acquired with ex = 324 nm.

167

Normalized Emisison
Intensity

1.0
0.8
0.6
0.4
0.2
0.0
500

550

600

650

700

Wavelength (nm)

Figure A-110. Phosphorescence emission spectrum of Gd-MP47 (1 mM) in 10 mM HEPES buffer (pH 7)
acquired with ex = 338 nm.
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Figure A-111. Phosphorescence emission spectrum of Gd-MP48 (1 mM) in 10 mM HEPES buffer (pH 7)
acquired with ex = 330 nm.
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